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Cancer continues to be the leading cause of disease-related death in children. 
Improving treatment protocols and outcomes for pediatric leukemia patients is of critical 
importance as acute lymphoblastic leukemia (ALL) accounts for 25% of all childhood 
cancers. ALL five-year relative survival rates have improved significantly in recent 
decades. However, many survivors suffer severe chronic physiological and psychological 
health problems, as well as poor social and economic outcomes. These consequences 
exemplify the continuing need to develop targeted, less toxic alternative therapeutics. 
Metabolomics, an emerging tool for precision medicine, can be used to analyze 
intracellular and extracellular environments, metabolic response to treatment, and pathway 
regulation in order to expand our understanding of the molecular mechanisms that drive 
pediatric cancer biology and identify and evaluate novel therapeutics. This study applied 
metabolomics approaches to precursor B-cell ALL (BCP-ALL) which accounts for 80% 
of ALL cases in children and adolescents. First, high-throughput screening (HTS) was used 
to identify a synergistic combination of non-toxic therapeutic alternatives to chemotherapy. 
Metabolomics and metabolic flux analyses of dimethylaminoparthenolide (DMAPT) and 
 vii 
shikonin (SHK) in BCP-ALL showed changes in amino acid, antioxidant, TCA cycle, and 
nucleotide metabolism. The shunting of glycolytic intermediates and glutaminolysis-
related metabolites to support proliferation was inhibited by DMAPT and SHK leading to 
apoptosis in BCP-ALL cells. Second, bone marrow-derived leukemia cells were collected 
from pediatric BCP-ALL patients at diagnosis. Stratifying patients by cytogenetic 
anomalies yielded unique metabolic profiles. Aberrations at the IGH locus are associated 
with poor outcomes, but no clear therapeutic targets have been identified. Assessment of 
individual metabolites indicated that amino acids, amino acid-related compounds, and 
some sugars were more abundant in patients with IGH locus aberrations. 
Phosphatidylcholines, phosphatidylethanolamines, and polar compounds involved in lipid 
metabolism were also increased, while nucleotides, diglycerides, and triglycerides were 
decreased in the IGH group. Pathway interrogation confirmed metabolic dysregulation. 
HTS indicated IGH mutant sensitivity to HSP, proteasome, mTOR, and HDAC inhibitors. 
Together, these analyses indicate the flexibility and utility of metabolomics to elucidate the 
underlying biology of pediatric leukemia and evaluate novel therapeutics to improve 
quality of life and long-term outcomes for childhood leukemia patients and adult survivors.  
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Chapter 1: Introduction  
1.1 CANCER 
It is estimated that in 2020, there will be nearly 2 million (1,806,590) cancer 
diagnoses and over half a million (606,520) cancer deaths in the United States (U.S.) [1]. 
Despite an overall decline in cancer-related deaths in recent decades, cancer remains the 
second leading cause of death overall, second only to heart disease. It is also the leading 
cause of death in Hispanic and Asian Americans, and individuals younger than 80 years of 
age [1, 2]. Moreover, the most recently reported five-year survival rate is 67% overall 
(2009 – 2015), indicating that nearly one third of people diagnosed with cancer succumb 
to the disease within the first five years [1]. 
Cancer comprises a vast diversity of neoplastic diseases defined most simply by the 
uncontrolled proliferation of abnormal cells. Biologically, cancers share at least six well-
established characteristics: resisting cell death, sustained proliferative signaling, evading 
growth suppressors, activating invasion and metastasis, enabled replicative immortality, 
and inducing angiogenesis [3, 4]. More recently, deregulating cellular energetics and 
avoiding immune destruction have appeared as emerging ‘hallmarks’ and genome 
instability and tumor-promoting inflammation have been identified as enabling 
characteristics [4]. In the last few decades, a great deal of research has focused on the 
genetic anomalies that permit and promote these shared cancer cell characteristics. From a 
genetics perspective, cancer can be understood as the accumulation of genetic lesions over 
time, giving rise to abnormal cellular proliferation [4-6]. The multi-stage model of 
carcinogenesis – encompassing initiation, promotion, and progression – is well-recognized 
 
Portions of this chapter have been previously published as the book chapter “Metabolomics, Bioactives, 
and Cancer” in the 2nd edition of Genomics, Proteomics, and Metabolomics in Neutraceuticals and 
Functional Food. Author contributions: Sweeney SR: Manuscript composition. DiGiovanni J: Critical 
revisions of the article. Tiziani S: PI, critical revisions of the article. 
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and has been widely accepted for many years [7-9]. As cells replicate, they become more 
prone to errors. Many errors naturally result in apoptosis or cellular senescence. In cancer, 
however, the accumulation of oncogenic errors results in tumor development [5, 6, 10, 11]. 
Current evidence suggests that genomic instability continues and may be accelerated 
during tumor progression, leading not only to the accumulation of submicroscopic lesions, 
but the loss of chromosomal integrity as well [8, 12]. Accordingly, cancer is typically 
thought of as a disease of old age or aging. The acceleration of the process that results in 
cancer in young individuals is not well understood. It cannot be attributed to germline 
mutations, or heritable cancers, as they only account for 7–8 % of childhood cancers [13, 
14]. There is compelling evidence that genetic mutations found predominantly in infants 
are initiated in utero (i.e. MLL translocations), but there is little indication that this is the 
case in most pediatric cancers [15, 16]. Pan-cancer genome and transcriptome analyses of 
pediatric leukemias and solid tumors found that only 45% of common genetic driver genes 
in children and adolescents overlapped with those found in adult studies [17]. Thus, 
translating findings from research and clinical trials in adults may not represent the best 
approach for treating pediatric cancer patients. Pediatric cancers may require distinct and 
unique techniques and approaches to understand the disease biology, develop treatment 
protocols, and improve long-term outcomes for childhood survivors. In fact, the National 
Cancer Institute (NCI) at the Nation Institutes of Health (NIH) has advocated for the 




1.2 PEDIATRIC CANCER 
Cancer is the second leading cause of death in American children aged 1 to 14 
years, surpassed only by accidents [1, 2]. Moreover, cancer is responsible for more than 
half (57%) of disease-related deaths in children [2]. For reasons that remain unclear, 
childhood cancer rates have steadily increased by 0.7% per year since 1975 [1]. Although 
diagnoses continue to rise, childhood cancer survival rates have improved significantly in 
recent decades. The increase in overall numbers has been driven by progress in five-year 
survival rates in leukemia, which are currently 87% for children (birth to 14 years) and 
73% for adolescents (15 to 19 years) [1]. However, many survivors suffer from poor long-
term outcomes including excess mortality and a wide range of late effects as a result of 
cancer treatment [19]. Pediatric cancer survivors have a significant increase in risk of all-
cause mortality up to 30 years after diagnosis [20]. When evaluated clinically, 98.2% of 
long-term survivors had at least one chronic health condition [21]. Adult survivors of 
childhood cancers suffer from a variety of life-threatening chronic health conditions 
including, pulmonary, cardiac, endocrine, and neurological disorders [21, 22]. Adult 
survivors are also prone to chronic conditions effecting quality of life including vision loss, 
hearing impairment, reproductive complications, diminished cognitive function, and 
mental health concerns [21, 23-25]. Optimization of timing, dosages, and combinations of 
existing therapeutics are predominantly responsible for improvements in patient outcomes 
[1, 26, 27]. However, less progress has been made in understanding the causes of childhood 
and adolescent cancers [20]. Further reducing cancer mortality will rely on new treatment 
paradigms based on childhood-specific cancer biology and targeted therapy [26].  
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1.3 LEUKEMIA 
1.3.1 Background  
Leukemia arises when white blood cells undergo malignant transformation while 
in circulation or in the bone marrow [28]. Because these cells are not confined to a single 
tissue, they do not form solid tumors [29]. Rather, immature malignant cells overpopulate 
the blood and bone marrow microenvironment, interfere with normal hematopoiesis, and 
ultimately overwhelm the circulatory and lymphatic systems [28, 30]. Thus, hematologic 
malignancies are unique in presentation [28, 29]. Leukemias are categorized as either 
lymphoblastic or myeloid depending on the cellular origin of malignant cells [30]. 
Lymphoblastic and myeloid leukemias are further categorized as either acute or chronic. 
Acute leukemias are characterized by the rapid proliferation of immature blast cells 
whereas chronic leukemias proliferate more slowly and malignant cells are more mature 
[28]. Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) require 
immediate intensive chemotherapeutic treatment to avoid the spread of malignant cells to 
vital organs and the central nervous system (CNS) [28, 30]. Conversely, chronic myeloid 
leukemia (CML) proliferates less rapidly and up to half of cases are diagnosed incidentally. 
Approximately 95% of CML cases can be managed with tyrosine kinase inhibitors, which 
specifically target malignant cells. Finally, chronic lymphoblastic leukemia (CLL) is 
diagnosed almost exclusively in older adults (65 years and older) and often requires little 
to no treatment to manage symptoms [29]. 
In 2020, an estimated 60,530 people will be diagnosed with leukemia in the U.S. 
[1]. It is also estimated that leukemia will result in the deaths of 23,100 people in 2020 [1]. 
Acute leukemia incidence is high in both children (0–14 years)  and adolescents (15–19 
years). Together, they account for 74% of cases, making ALL predominantly a childhood 
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disease [20, 31]. In addition, ALL is also the most common malignancy in young people, 
accounting for 28% of all cancer incidence in children [1, 19, 20]. Acute myeloid leukemia 
(AML) is the fifth most common malignancy, accounting for approximately 5% of all 
cancers in children. Overall, incidence of ALL and AML decrease with age. For adolescent 
boys between 15 and 19 years of age, ALL is the fourth most common cancer accounting 
for 9% of all cancers and AML is the seventh most common cancer accounting for 4% of 
cancer incidence. Together, ALL and AML make leukemia one of the most common 
cancers in adolescent males. In adolescent girls, ALL is the sixth most common cancer 
accounting for 5% of incidence and AML is eighth, also with approximately 5% of cancer 
incidence [19]. 
In the last three decades, significant improvements in chemotherapeutic regimens 
have vastly improved leukemia patient prognosis. The five-year survival rates for children 
and adolescents rose from 41% in the 1970s to 71% in the early 2000s [20, 26, 32]. 
Presently, five-year survival rates are 87% and 73% for children and adolescents, 
respectively [1]. Nonetheless, cancer, including leukemia, continues to be the leading cause 
of disease-related death in children [1, 33]. 
1.3.2 Urgent need to improve long-term outcomes for pediatric leukemia survivors 
Despite high rates of remission, the Childhood Cancer Survivor Study reported that 
the primary cause of death in leukemia survivors was disease recurrence and secondary 
tumorigenesis [34]. Additionally, pediatric leukemia survivors suffer from a number of 
severe chronic health problems including musculoskeletal, cardiac, and neurological 
conditions [34-36]. Childhood survivors also struggle with social, emotional, 
psychological, academic, and economic challenges, including lower rates of marriage and 
college graduation when compared to their healthy siblings [34, 37-39]. These 
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consequences are directly connected to the administration of highly toxic 
chemotherapeutics at young age [35-37, 39]. Thus, new strategies are needed to improve 
long-term quality of life for childhood cancer survivors [34, 40].  
1.3.3 Risk stratification has reduced pediatric leukemia mortality  
Patient stratification based on risk-directed treatment, coupled with improvements 
in supportive care for children and adolescents, has greatly reduced mortality over the last 
three decades [33, 40]. For risk-directed treatment, leukemia patients are assigned a 
preliminary risk group based on select clinical parameters prior to induction therapy [41]. 
Most commonly, patients are classified into two groups: standard risk (SR) or high risk 
(HR), or four groups by the addition of: very high risk (VHR) and low risk (LR). 
Conventional, widely-accepted risk factors at diagnosis include: sex, age, white blood cell 
count (WBC count), and immunophenotype (B-cell or T-cell), where male, increasing age, 
higher WBC count, and T-ALL are considered unfavorable [41, 42]. More recently, 
response to induction therapy has been factored into patient risk assessment [40, 42]. 
Treatment response, measured as minimal residual disease (MRD), has proven to be a 
useful tool for risk stratification during treatment. MRD can be assessed by either 
polymerase chain reaction (PCR) or flow cytometry to determine the number of remaining 
leukemia cells following induction therapy. PCR is more sensitive than flow cytometry but 
is more costly and time consuming. Most commonly, MRD negative is defined as one or 
fewer leukemia cells per 10,000 healthy cells, or ≤10-4, which is largely determined by the 
limit of detection (LOD) of the assays [43]. In the U.S. and most industrialized countries, 
pediatric institutions, including major research consortiums like Children’s Oncology 
Group (COG) and St. Jude’s Children’s Research Hospital, stratify patients by MRD 
following induction therapy [40, 43]. It should be noted that no consensus has been reached 
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establishing ideal timing and thresholds for MRD measurements [42, 43]. Genetic 
anomalies have also been used to stratify patients for risk-directed therapy [40, 42]. Much 
like MRD, little consensus has been reached regarding the best way to integrate established 
clinical parameters and genetic risk factors to maximize improvements in patient outcomes 
[42]. Nonetheless, stratification by genetic and molecular factors can be useful for both 
risk-directed therapy and targeted drug development to maximize HR (and VHR) patient 
survival and improve long-term quality of life for all leukemia patients [40]. 
1.3.4 Leukemia is characterized by significant genetic alterations 
Hematological malignancies, like solid tumors, are characterized by genomic 
instability and mutations that cooperate to promote leukemogenesis [4, 44-47]. Nearly all 
leukemias are driven by a limited number of gross chromosomal changes [42, 45-47]. 
There are two main categories of chromosomal aberrations, changes in chromosome 
number giving rise to aneuploidy and structural changes which include translocations, 
deletions, insertions, and inversions [42, 46-49]. Although most leukemias have a small 
number of mutations, in experimental models, most primary chromosomal alterations do 
not induce leukemia alone. Instead, they require one or more secondary mutations that 
cooperatively result in leukemogenesis [42, 47]. Most gross chromosomal anomalies have 
not been thoroughly investigated as therapeutic targets because they do not result in 
leukemogenesis alone. Furthermore, explicit targets can be challenging to identify since 
large regions of the genome are effected [15]. Nevertheless, rates of incidence and 
correlations with patient outcomes suggest chromosomal anomalies are crucial for 
leukemogenesis and future research should focus on elucidating the underlying molecular 
mechanisms and identifying potential therapeutic targets [15, 48].   
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Several complimentary molecular techniques have been employed to characterize 
genetic anomalies in leukemia and improvements in cytogenetic tools have made it 
possible to identify chromosomal anomalies with a high degree of accuracy and specificity 
[47, 48]. Standard cytogenetic techniques used clinically include karyotyping, Giemsa 
banding (G-banding), fluorescence in situ hybridization (FISH), and comparative genome 
hybridization (CGH) [47]. In conjunction with karyotyping, FISH is most commonly 
employed clinically to detect the presence and location of specific gene sequences on 
chromosomes [50]. G-banding and multiplex FISH can both be used for detecting 
chromosome number and morphology, but at the cost of lower resolution and sensitivity 
[47]. Locus-specific FISH has higher resolution and sensitivity, and can detect specific 
DNA sequences, but has narrower application [47]. CGH can detect a broad array of 
unbalanced losses or gains of genetic material across the genome with very high resolution 
[47, 51]. These techniques can also be combined with PCR and multiplex ligation-
dependent probe amplification (MLPA) which provide additional high-resolution genetic 
information [47]. Lastly, the falling costs of whole genome sequencing has made it possible 
to sequence all or large parts of individual genomes to identify the unique genetic profile 
of patients. While genomic sequencing techniques employed by researchers have identified 
an impressive number of novel anomalies, none of these techniques have become routine 
in clinical application [52, 53].  
 
1.4 CANCER AS A DISEASE OF ABERRANT METABOLISM 
Prior to a modern understanding of molecular biology and the genetic mutations 
and chromosomal anomalies associated with cancer, it was thought to be a metabolic 
disorder. In 1956, Otto Warburg observed that cancer cells produced copious amounts of 
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lactate from glucose even in the presence of adequate oxygen [54, 55]. Warburg 
hypothesized that cancer was caused by defective mitochondria leaving cells unable to 
efficiently produce energy via the canonical Tricarboxylic Acid Cycle (TCA) and 
Oxidative Phosphorylation (OXPHOS) pathways, both of which take place in the 
mitochondria. More recently, metabolic reprogramming (along with evasion of immune 
destruction) has been recognized as an emerging hallmark of cancer [3, 4]. Cancer cells do 
not engage in anaerobic glycolysis because they lack the ability to completely oxidize 
glucose. Instead they engage in both anaerobic and aerobic metabolism simultaneously to 
meet their energetic and proliferation needs. Cancer cells reprogram their metabolism to 
enhance the uptake of both glucose and glutamine to promote biomass production and 
sustained proliferation without the complete oxidation of substrates [54-59]. 
Reprogramming of major metabolic pathways can produce sufficient energy via glycolysis 
while simultaneously exploiting the TCA cycle for the interconversion of metabolites to 
be harvested for biosynthesis of macromolecules [59, 60].  
In addition, cancer cells have been shown to reprogram the metabolism of 
neighboring cells for their own benefit [4]. For example, leukemia cells can evade and 
overcome asparaginase-induced stress with the support of other cells in the 
microenvironment [61, 62]. Mesenchymal stem cells (MSC) protect acute lymphoblastic 
leukemia (ALL) cells from asparaginase treatment by upregulating their own asparagine 
synthetase (ASNS) in co-culture experiments [63]. Similarly, adipocytes, which are 
abundant in the bone marrow tumor microenvironment, also provide asparaginase 
resistance for ALL cells by secreting glutamine into the extracellular matrix [64]. And, 
CLL cells depend on stromal cell-derived cysteine to synthesize glutathione for protection 
from stress induced by reactive oxygen species (ROS) [65]. 
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Cancer research has come full circle and returned to understanding cancer not only 
in the context of mutations and faulty proteins, but also as a metabolic disease where 
cellular energetics are used to feed the insatiable appetites of malignant cells, metabolites 
are hijacked and used to stoke the flames of cancer factories, and healthy cells are 
reprogrammed to support their greedy neighbors. In this way, cancer can be understood as 
a disease that is initiated by an accumulation of mutations that culminate in the metabolic 
dysregulation of cancer cells and surrounding normal cells that have been recruited and 
reprogrammed to support the growth and proliferation of their malignant neighbors. 
 
1.5 METABOLOMICS 
1.5.1 The short history of metabolomics 
While the identification and monitoring of metabolites is not a new concept in 
science or medicine, untargeted, comprehensive metabolite analysis, commonly designated 
metabolomics, has only become possible in more recent years [66]. For decades, 
biochemists have evaluated metabolites found in blood, urine, and tissue samples to 
diagnose diseases, monitor cellular response to treatments, and understand pathway 
regulation [67, 68]. In fact, with the proper tools, metabolites can provide insight into 
processes occurring at subcellular, cellular, tissue, organ, and organism levels [66, 69]. 
Historically, the instrumentation and computational technologies available have meant that 
it was only possible to measure a small number of metabolites or classes of metabolites 
that were determined a priori [70, 71]. As a consequence, metabolite identification gained 
little attention. Rather, biological research has focused on identification of novel genetic 
mutations and later aberrant protein activities [72]. The complete sequencing of the human 
genome gave rise to the systems biology approach and ‘omics’ disciplines were born. 
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Metabolomics is the newest of the pure ‘omics’ (genomics, transcriptomics, proteomics, 
and metabolomics) [72-74]. In 1999, Nicholson and colleagues proposed the term 
metabonomics, which they defined as “the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or 
genetic modification” [75].  Shortly after, Oliver Fiehn presented a simpler and broader 
alternative, describing metabolomics as the “…comprehensive analysis in which all the 
metabolites of a biological system are identified and quantified” [66]. Metabolomics has 
become the more universally accepted term when addressing the complexity of 
comprehensively evaluating metabolites and will be used in this sense henceforth [70]. 
Great efforts have been made to create libraries of complete genomes, proteomes, 
transcriptomes, and metabolomes in order to provide standards for comparison [76-78]. 
Furthermore, future integration of libraries will elucidate biological perturbations across 
all levels of expression [79]. Much work still remains, for the metabolome in particular, as 
it is by far the most complex in terms of chemical diversity, abundance, and dynamism. 
Moreover, consensus regarding reporting standards and analytical methods are still under 
development [71, 77, 80, 81]. The number of metabolites in mammalian samples is 
enormous and remains mostly unknown, with estimates ranging from thousands to 
hundreds of thousands of small molecules [67]. Combining several analytical platforms, 
4229 and 2651 metabolites have been identified in the human serum and urine 
metabolomes, respectively [82, 83]. Even more metabolites are detectable in both serum 
and urine, but have not yet been annotated [71, 81]. Furthermore, the chemical diversity of 
the metabolome coupled with the concentration range of metabolites in biological samples 
make it virtually impossible to comprehensively measure every metabolite with a single 
platform or analysis [67, 71, 74, 84, 85]. Instead, platforms and analyses should be applied 
in concert to provide complementary data sets [86]. Advancements in nuclear magnetic 
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resonance (NMR) spectroscopy and mass spectrometry (MS) instrumentation have 
contributed most significantly to the emergence and development of metabolomics [70, 86, 
87]. In addition, because these instruments generate large amounts of data, in some cases 
tens of thousands of data points in a single scan, advances in computation and statistical 
methods have made it possible to address the complexity and size of the information 
generated [81, 88, 89].  
1.5.2 Nuclear magnetic resonance spectroscopy 
High-resolution NMR spectroscopy is a popular analytical technique that continues 
to be widely used in metabolomics research [90-92]. NMR, also known as MRS (magnetic 
resonance spectroscopy) [93], takes advantage of the inherent magnetic properties of 
certain nuclei [94]. In particular, nuclei that have a nuclear spin, I, equal to ½ are easily 
detected with NMR spectroscopy. Common spin ½ nuclei include 1H, 13C, 15N, and 31P; 
the most abundant and widely used in metabolomics is 1H-NMR. Under normal conditions 
nuclear spins are completely random and, therefore, do not lead to bulk magnetic 
properties. However, when subjected to a strong, static magnetic field, typically denoted 
B0, the nuclear spins will align and precess around the magnetic field at a characteristic 
frequency, known as their Larmor frequency [95]. Application of a much weaker, transient 
oscillating radio frequency (RF) pulse results in the excitation of the nuclei [96]. Pulses are 
typically applied perpendicular to the static magnetic field, B0, which changes the 
orientation of the magnetization. The removal of the RF pulse causes the excited nuclear 
spins to relax according to their T1, spin-lattice, and T2, spin-spin relaxation times. T1 is a 
measure of the time it takes for the spins to return to their lower energy states and T2 is a 
measure of the loss of coherence of the spins that occurs after the removal of the RF pulse 
[97]. This relaxation is observed as a free induction decay (FID). After collection, the FID 
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can be Fourier transformed to convert the signal from the time domain into the frequency 
domain, resulting in a classic NMR spectrum, typically given in ppm. 
The NMR spectrum contains a wealth of information including the structure and 
abundance of the molecules present. The chemical shift of peaks in an NMR spectrum 
depends on the local environment the nucleus experiences [94]. Nuclei that have greater 
electron densities will be found at lower ppm, whereas electron deficient nuclei will be 
shifted to higher ppm [98]. Furthermore, sensitive nuclei can couple with neighboring 
nuclei to create a multiplet instead of a single peak [94]. This phenomenon, known as J-
coupling, is due to overlapping electron orbitals and can be used for structural identification 
[99, 100]. Due to these characteristic properties, NMR continues to be a powerful analytical 
chemistry tool to elucidate molecular structure [94, 101]. In fact, it is still used extensively 
for structural and functional analysis of proteins [102]. In addition, NMR peak areas are 
directly proportional to the number of sensitive nuclei making it an inherently quantitative 
technique. Incorporating a single standard compound, usually TSP (Trimethylsilyl 
propanoic acid) or DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid), at a known 
concentration is sufficient to correct chemical shift and extrapolate absolute concentrations 
of all positively identified metabolites [91]. 
NMR spectroscopy is one of the most extensively used analytical techniques for 
metabolite identification because it is so well suited for molecular analysis. The application 
of NMR to biological samples was first explored by Nicholson et al. in the late 1990s [103]. 
It is particularly well suited for an ‘omics’ approach because it is naturally untargeted and 
thus, completely unbiased [91]. If a metabolite is present at an adequate concentration, it 
will be detected. Furthermore, relatively minimal sample preparation is required [90, 91]. 
This results in highly efficient and reproducible sample preparation [86]. As a result, NMR 
is extremely reliable and ideal for absolute quantification of metabolites [89, 90]. The 
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inherently untargeted nature of NMR spectroscopy allows for the identification of both 
metabolites of interest and those outside hypothesized outcomes.  
The most significant limitation of NMR spectroscopy is sensitivity [91, 96]. While 
advances in superconducting materials, magnet strength and quality, cryogenic probe 
technology, and pulse sequences have vastly improved sensitivity, MS remains superior 
for detection of very low abundance metabolites [91, 96, 101]. Superconducting materials 
and improvements in magnetic field homogeneity have created extremely powerful 
instruments. There are now magnets that can generate a magnetic field of 25.9 Tesla which 
gives a resonance frequency of 1.1 GHz (gigahertz). Technological advances in pulse 
sequences and pulsed-field gradients, used to select for desired signal have significantly 
enhanced signal quality [101, 104, 105]. Likewise, advanced water suppression techniques, 
such as excitation sculpting, have also improved NMR spectra [106]. Lastly, advances in 
probe quality and size have improved excitation profiles and sensitivity, and decreased 
sample volumes [96]. Typically, NMR requires rather large sample volumes, on the order 
of 200 µL, but newer probes can obtain high quality signals with as little as 30 µL [107]. 
Nonetheless, spectra are still dominated by higher abundance metabolites and complex 
samples often require some degree of deconvolution to identify less abundant molecules 
[91]. Additionally, because no separation techniques are employed, lower abundance 
metabolites may be undetectable due to overlap with more abundant molecules. 
1.5.3 Mass spectrometry 
In the simplest terms, mass spectrometers manipulate electromagnetic fields that 
apply forces to ionized particles. Because the forces being applied are dependent on the 
mass and the charge of molecules, mass analyzers are designed to separate ions by their 
mass-to-charge ratio (m/z). While NMR spectrometers primarily vary in the magnetic field 
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strength and the properties of the probe, there is a great deal of diversity in mass analyzers. 
Because each have their strengths and weaknesses, different instrumentation can be 
selected depending on the desired properties. Common mass analyzers utilized in 
metabolomics research include: Triple Quadrupole (QqQ-MS), Time of Flight (TOF-MS), 
Quadrupole Time of Flight (QTOF-MS), Fourier Transform Ion Cyclotron Resonance (FT-
ICR/MS), and Orbitrap [69]. Quadrupole mass analyzers function similar to a filter, only 
stabilizing a selected mass-to-charge ratio that will reach the detector. On the other hand, 
time of flight mass analyzers separate ions based on the time it takes to reach the detector. 
FT-ICR/MS and Orbitrap mass analyzers trap and manipulate ions, which provides the 
highest mass accuracies, whereas others are preferred because of their rapid scanning rates 
and broad m/z detection ranges [69]. 
Although direct injection methods, often called ‘shotgun’ techniques, are used in 
metabolomics, more often mass spectrometers are coupled with either gas (GC) or liquid 
chromatography (LC), especially ultra-high performance liquid chromatography (UPLC or 
UHPLC), to enhance chemical separation of complex biological matrices [69, 108]. This 
adds an additional layer of diversity to developing and applying MS methods to 
metabolomics. Although GC-MS was developed and gained popularity before LC-MS, the 
latter has been shown to deliver superior separation to a broader diversity of compounds, 
whereas GC-MS is primarily limited to volatile molecules or requires derivatization of non-
volatile compounds [71]. LC-MS requires an interface between the chromatography 
column and the mass analyzer because the eluted metabolite must be ionized and converted 
into the gas phase before detection. There are three common interfaces: atmospheric 
pressure photo ionization (APPI), atmospheric pressure chemical ionization (APCI), and 
pneumatically assisted electrospray ionization (ESI). Of these, ESI is by far the most 
commonly used in metabolomics analyses and across other disciplines [69, 108]. 
 16 
To add another layer of complexity, mass spectrometers can be used in tandem 
(MS/MS) to positively identify ions by their fragmentation pattern. Typically, the first MS 
isolates molecular ions and the second MS detects ion fragments in order to positively 
identify metabolites by combining the data from the molecular ion and its characteristic 
fragmentation pattern. Alternatively, positive identification can be performed by matching 
the retention time to a standard reference library of compounds. Internal standards can be 
spiked directly into the sample matrix or a mass spectral metabolite library of standards 
can be acquired under identical parameters to build a reference library of accurate masses 
and retention times. 
Mass spectrometers have the advantage of essentially unparalleled sensitivity, 
making MS an ideal complement to NMR. In addition, lipid analysis, which is difficult 
with NMR, is possible with MS, making it an extremely valuable technique for lipidomics 
[109-112]. MS analysis is not without of challenges. Aside from the great diversity in mass 
analyzer types and coupled techniques, sample preparation is often tedious and can result 
in significant metabolite loss [90]. Furthermore, chromatography column selection, elution 
solvents, and analysis time all introduce limitations for untargeted analysis and can lead to 
undesired matrix effects [71]. While it is currently impossible for a single MS analysis to 
detect all the metabolites in any given sample, the remarkable sensitivity coupled with 
chromatographic techniques that separate overlapping metabolites make GC-MS and LC-
MS valuable techniques for metabolomics. MS analysis is not well suited for absolute 
quantification due to variable ionization efficiencies which significantly limits its 
application, in particular for biomarker identification [90]. For this reason, concentration 
curves and internal standards labeled with stable isotopes are required to accurately 
quantify metabolites, when necessary [90]. 
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1.5.4 Technological advancements 
Advances in computer programming and processing speeds have made untargeted 
metabolite analysis possible [70, 74]. For example, a single NMR spectrum can contain 
more than 64,000 complex data points [76, 113]. Similarly, LC-MS is able to separate and 
detect tens of thousands of features from a single complex sample [71, 86, 114]. Without 
computers and software capable of processing this information, it would be impossible to 
advance the field of metabolomics. 
Multivariate analysis can be applied to multiple spectra for pattern recognition [70]. 
These methods fall under two broad categories, unsupervised and supervised, the most 
common of which are principal component analysis (PCA) and partial least squares 
discriminant analysis (PLSDA), respectively [89, 90]. Both are powerful statistical tools 
that can be used to observe global differences among groups [90, 115]. Supervised and 
unsupervised methods analyze entire spectra to evaluate statistical trends without 
identification of individual metabolites. PCA is typically considered more powerful than 
PLSDA because it is completely unbiased and is usually applied first to determine if 
inherent grouping exists within the data [85]. On the other hand, with PLSDA, grouping is 
predetermined and a predictive model is developed based on the common characteristics 
of each group [85, 116]. A related supervised method, orthogonal PLSDA (O-PLSDA), is 
common in metabolomics research [85, 115, 117]. In order to avoid bias from higher 
abundance metabolites, it is important to apply normalization and scaling functions prior 
to evaluation with either supervised or unsupervised methods [78]. Care must be taken to 
avoid overfitting the data when applying supervised methods to prevent false positive 
results [118]. 
Metabolite identification is one of the biggest challenges in metabolomics [81, 
114]. Progress in the development of metabolome databases and libraries has significantly 
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improved identification of metabolites detected by either NMR or MS [77, 80]. The most 
comprehensive human database is the Human Metabolome Database (HMDB) with a 
catalog of more than 100,000 metabolites [119-122]. Several smaller databases have also 
become publicly available in recent years. These resources often vary by organism or 
analytical platform. Some of the most valuable are metabolic pathway databases, such as 
Kyoto Encyclopedia of Genes and Genomes (KEGG) [123-125] and HumanCyc [126], and 
spectral libraries, such as Metlin [127] and mzCloud. More recently, faster tools have been 
developed to interrogate these databases including R-Metabolist [128, 129]. Frequently, 
the majority of compounds detected are not present in any database [71, 81]. To alleviate 
this deficiency, the Metabolomics Standards Initiative (MSI) has been formed and proposes 
thorough minimum reporting standards to maintain consistency between laboratories 
employing different instruments and methods [130, 131]. 
1.5.5 Integration of clinical parameters and metabolic profiling 
Large-scale, untargeted profiling methods, including genomics, transcriptomics, 
proteomics, and metabolomics have been successfully used to elucidate molecular and 
metabolic cellular processes that are altered in disease states and identify potential targets 
for therapy [132, 133]. Metabolite concentrations have already been shown to be sensitive 
markers for genomic changes and in the context of cancer, an increasing amount of 
evidence indicates that major alterations in cancer cell metabolism contribute to oncogenic 
signaling and support cancer cell proliferation [134]. The main analytical platforms for 
metabolic profiling are mass spectrometry (MS) and nuclear magnetic resonance 
spectroscopy (NMR). MS, especially coupled to liquid chromatography (LC), is 
characterized by unparalleled sensitivity, while NMR is inherently quantitative and 
seamlessly translates in vivo [135, 136]. High-throughput, untargeted experiments allow 
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for the mining of not only known, but also unknown, unpredicted, and novel pathways of 
interest to provide new insights into disease [92, 137, 138]. 
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Chapter 2: Identification of a synergistic combination of 
dimethylaminoparthenolide and shikonin alters metabolism and inhibits 
proliferation of pediatric precursor B-cell acute lymphoblastic leukemia 
2.1 ABSTRACT  
Exploiting metabolic vulnerabilities of cancer cells with non-toxic, plant derived 
compounds constitutes a novel strategy for both chemoprevention and treatment. A high-
throughput screening approach was used to evaluate a library of natural products to 
determine the most synergistic combination in precursor B-cell acute lymphoblast 
leukemia. Dimethylaminoparthenolide and shikonin effectively inhibited proliferation 
resulting in cell death in primary and immortalized leukemia cells, while having negligible 
effects on normal cells. Dimethylaminoparthenolide and shikonin have been shown 
separately to inhibit cell survival and proliferative signaling and activate tumor suppressors 
and pro-apoptotic pathways. Untargeted metabolomics and metabolic flux analysis with 
stable isotopically labeled glucose and glutamine exhibited a global shift in metabolism 
following treatment. Pathway analysis indicated significant differences in amino acid, 
antioxidant, TCA cycle, and nucleotide metabolism. Together, dimethylaminoparthenolide 
and shikonin reduced the shunting of glycolytic intermediates into the pentose phosphate 
pathway for biosynthetic purposes. Similarly, the incorporation of glutamine and 
glutamine-derived metabolites into purine and pyrimidine synthesis was inhibited by the 
combination of dimethylaminoparthenolide and shikonin, effectively impeding 
biosynthetic pathways critical for leukemia cell survival. This approach demonstrates that 
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a synergistic pair of compounds with malignant cell specificity can effectively target 
metabolic pathways crucial to leukemia cell proliferation and induce apoptosis. 
 
2.2 INTRODUCTION 
Cancer is the primary cause of death in children and adolescents ages 1 – 19 [26]. 
Leukemia is the most common pediatric cancer, accounting for nearly one-third of all 
cancers in children [19]. Current treatment strategies involve a very intense, risk-directed 
induction phase at the outset of treatment [139]. This approach effectively induces 
remission in most patients but is highly toxic and consequently results in significant short- 
and long-term side effects [34, 140]. Among childhood leukemia survivors, 75% report a 
least one chronic condition 5 – 14 years post-diagnosis, a figure that climbs to 85% by 25 
– 36 years [141]. Even more concerning, incidence rates have continued to rise since 1975, 
indicating a persistent and growing problem [19]. Given the numerous adverse effects of 
current strategies, there is a continued need to identify compounds that are 
chemopreventive and can be used as adjuvant therapies to ameliorate the consequences of 
treatment [142-144]. 
Diets rich in fruits and vegetables have been shown to reduce cancer risk due to an 
abundance of phytochemicals – non-nutritive, plant-based bioactive chemical compounds 
[142]. In vitro experiments and in vivo animal models of cancer prevention and progression 
have established that many phytochemicals, also called natural products, possess potent 
anti-cancer activities [142, 145]. These compounds have a variety of biological activities 
including functioning as antioxidants [146], reducing inflammation [147], regulating signal 
transduction pathways [148], promoting terminal differentiation [149], inhibiting 
proliferation [150], inducing apoptosis [151], and suppressing angiogenesis [152]. Natural 
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products have also inspired the pharmaceutical industry for mimetics and synthetic analogs 
[153]. Many drugs approved by the US Food and Drug Administration in recent decades 
have been natural products and derivatives thereof; Chemotherapeutic examples include 
etoposide, vincristine, vinblastine, and paclitaxel [145, 153]. 
 Early research characterized cancer as a disease of aberrant metabolism [54, 55]. In 
recent years, this characterization has been reinvigorated and metabolomics has become a 
valuable tool for the study of cancer cell metabolism, the tumor microenvironment, drug 
discovery, and biomarker investigation [154]. Metabolomics is the analysis of all the small 
molecules present in a biological sample. Metabolite levels reflect the amalgamation of 
gene variants, gene expression, pathway activity, and enzyme kinetics, and as such, serve 
as a direct signature of biochemical activity in a cell, tissue, organ, or organism [81].  
In this study, a high-throughput screening (HTS) approach was used to 
simultaneously analyze 136 compounds in a natural product library (NPL) in patient-
derived precursor B-cell acute lymphoblastic leukemia (BCP-ALL), immortalized BCP-
ALL cell lines, and bone marrow-derived normal cells. This technique has been used 
extensively in drug discovery because it allows concurrent analysis without determining a 
priori which compound to investigate in-depth [150, 155]. The top candidate compounds 
were evaluated at varying concentrations and ratios to identify the optimal combination. 
Dimethylaminoparthenolide (DMAPT) and shikonin (SHK) were selected as the most 
promising synergistic pair. Untargeted metabolomics and metabolic flux analysis (MFA) 
were performed following single and combination treatment of DMAPT and SHK to 
determine the global impact these compounds have on BCP-ALL metabolism. The results 
of this research demonstrate the efficiency and efficacy of combining untargeted analyses 
in a data-driven process to identify chemotherapeutic strategies that ameliorate the global 
toxicity of currently employed compounds. 
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2.3 MATERIALS AND METHODS 
2.3.1 Reagents and chemicals 
A natural product library (NPL) consisting of 131 structurally diverse compounds 
(Table A1) was purchased from Selleck Chemicals (Houston, TX, USA). Five additional 
natural products were purchased from Cayman Chemical Company (Ann Arbor, MI, 
USA): betulinic acid, caffeic acid phenylethyl ester, genistein, resveratrol, and shikonin. 
The library was diluted and configured from a 96-well format into 384-well microplates at 
a stock concentration of 2.5 mM in dimethyl sulfoxide (DMSO). Each stock plate contained 
two treatment replicates and control wells. Microplates were sealed and stored at -80°C 
until use. Plates were only thawed and used once to prevent efficacy loss from repeated 
freeze-thaw cycles. Tissue culture reagents were purchased from GE Healthcare 
Biosciences (Pittsburg, PA, USA) unless specified otherwise. Mass spectrometry grade 
water, acetonitrile, methanol, 2-propanol, chloroform, ammonium acetate, ammonium 
formate, and formic acid, as well as molecular biology grade ethanol, hydrochloric acid 
(HCl), DMSO, and 2,6-di-tert-butyl-4-methylphenol (BHT) were purchased from Thermo 
Fisher Scientific (Waltham, MA, USA). Commercial calibration solutions for the mass 
spectrometer were also purchased from Thermo Fisher Scientific. Ammonium bicarbonate 
was purchased from Sigma-Aldrich Corporation (St. Louis, MO, USA). The following 
isotopically labeled compounds were purchased from Cambridge Isotope Laboratories 
(Tewksbury, MA, USA): 13C5,15N2-glutamine, 13C6-glucose, 13C1-glucose, D4-alanine, D3-
serine, D2-glycine, D4-citric acid, D3-malic acid, D4-succinic acid, D2-fumaric acid, D3-
aspartic acid, D4-L-lysine, D4-cystine, D3-DL-glutamic acid, D5-glutamine, and D5-L-
tryptophan.  
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2.3.2 Cell culture 
Eight human cell lines were used for screening purposes, five pediatric BCP-ALL 
and three bone marrow-derived normal (Table 2.1). Patient-derived BCP-ALL cells from 
a collaboration with Dell Children’s Blood and Cancer Center (CBCC; Austin, TX, USA) 
were isolated from fresh bone marrow aspirates by Ficoll-Paque (GE Healthcare Bio-
sciences AB, Uppsala, Sweden) density centrifugation at the time of diagnosis and cultured 
for 24 – 48 hours prior to screening. IRB approval was granted prior to collection of patient-
derived samples all of which were de-identified by CBCC staff before transfer to the 
laboratory.  
 
Table 2.1: Human cells screened with NPL and top candidate combinations are 
representative of the bone marrow microenvironment in pediatric leukemia  
Immortalized cell lines were expanded, tested for mycoplasma, and stored cryogenically 
prior to screening. Primary cells were collected fresh from bone marrow aspirates and 
cryogenically stored until screening. Cells were cultured under standard conditions for a 
minimum of 48 hours prior to screening. BCP-ALL, precursor B-cell acute lymphoblastic 
leukemia. 
 
Name Type Status 
Kasumi-2 BCP-ALL Pediatric, Immortalized 
KOPN-8 BCP-ALL Pediatric, Immortalized 
NALM-6 BCP-ALL Pediatric, Immortalized 
RCH-ACV BCP-ALL Pediatric, Immortalized 
Reh BCP-ALL Pediatric, Immortalized 
Patient 1 BCP-ALL Pediatric, Primary 
Patient 2 BCP-ALL Pediatric, Primary 
Patient 3 BCP-ALL Pediatric, Primary 
Patient 4 BCP-ALL Pediatric, Primary 
MSC Mesenchymal Stem Cell Bone marrow derived, Primary 
HS-5 Stromal Bone marrow derived, Immortalized 
HS-27A Stromal Bone marrow derived, Immortalized 
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Immortalized cell lines were expanded, tested for mycoplasma, and stored 
cryogenically prior to screening. Primary cells were collected fresh from bone marrow 
aspirates and cryogenically stored until screening. Cells were cultured under standard 
conditions for a minimum of 48 hours prior to screening. Suspension cell lines were 
cultured in RPMI-1640 medium supplemented with 10% characterized fetal bovine serum 
(FBS) and 2 mM L-glutamine. Adherent cell lines were cultured in DMEM medium 
supplemented with 10% mesenchymal stem cell-qualified FBS and 2 mM L-glutamine. 
Patient-derived cells were cultured in Stem Span II Serum-Free Expansion Medium 
(StemCell Technologies, Vancouver, Canada). Stable isotope labeling experiments were 
performed in RPMI-1640 medium without glucose or glutamine (MP Biomedicals, Santa 
Ana, CA, USA) supplemented with 10% dialyzed FBS and either 13C5,15N2-glutamine or 
13C6-glucose. All cells were incubated under standard conditions at 37°C and 5% CO2. 
Suspension cells were maintained at a concentration range of 200,000 to 2 x 106 cells/mL 
and adherent cells were split via trypsinization at 70 – 90% confluency.  
2.3.3 High-throughput screening 
To minimize variability, cells were pre-conditioned for 48 hours in fresh medium. 
An automatic pipetting system (VIAFLO ASSIST; INTEGRA Biosciences, Hudson, NH, 
USA) was used to ensure consistent cell seeding. Cells were seeded into 384-well white 
polystyrene microplates (Thermo Fisher Scientific, Waltham, MA, USA) at either 2,500 or 
5,000 cells/well for leukemia and normal cells, respectively. A lower seeding density was 
used for leukemia cells due to their high proliferation rates relative to non-malignant cells. 
A cell density experiment was performed initially to ensure appropriate seeding for all cell 
lines despite differences in doubling times. For each cell line, a total of 6 plates were seeded 
to obtain four replicates at three time points: 12, 24, and 48 hours. Following plating, cells 
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were incubated for 8 – 12 hours to equilibrate. Next, each well was treated simultaneously 
using a 384-channel electronic pipette platform (VIAFLO 384; INTEGRA Biosciences) at 
a final concentration of 10 µM. 
Cell viability was assessed at each timepoint by ATP luminescence (CellTiter-Glo; 
Promega, Madison, WI, USA) with a multimode microplate reader (Tecan Spark; Tecan, 
Männedorf, Switzerland). The manufacturer’s protocol was followed for the CellTiter-Glo 
(CTG) assay. Briefly, in a dark room, plates were equilibrated to room temperature for 30 
minutes prior to the addition of the CTG reagent. Reagent was dispensed using the 
automatic pipetting system described above. Plates were placed on a platform mixer 
(MixMate; Eppendorf, Hamburg, Germany) for two minutes at 700 rpm to homogenize 
lysate. Following mixing, plates were equilibrated for an additional 10 minutes to allow 
the luminescence signal to stabilize. Endpoint luminescence with a 1000 ms integration 
time was recorded as a surrogate for cell viability. A Dixon’s Q test was applied to all raw 
data points prior to normalization to identify outliers that could lead to potential false 
positive or false negative results [156]. Luminescence intensities were normalized to the 
vehicle control for each plate. Averages and standard deviations were calculated for each 
compound, time point, and cell line. Statistical significance was determined using a two-
tailed, Student’s t-test with a standard α of 0.05.  
2.3.4 Combination screening 
A second round of screening was performed on the top candidates identified from 
the single compound screening. To be considered a candidate for combination screening, 
compounds were required to meet a threshold of >25% growth inhibition in patient-derived 
leukemia cells. The candidate compounds were then divided into two groups based on their 
toxicity in normal cells. Compounds that inhibited normal cell growth <50% were 
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considered selectively toxic to leukemia cells whereas those that inhibited normal cell 
growth >50% were categorized as broadly toxic at 10 µM. Additionally, for each of the 
candidate compounds, the difference in toxicity between leukemia and normal cells was 
calculated. The compound with the greatest viability difference was selected as the top 
candidate. For combination screening, selectively toxic compounds were evaluated at 
concentrations ranging from 250 nM – 15 µM (250 nM, 500 nM, 750 nM, 1 μM, 5 μM, 10 
μM, 15 μM). Compounds categorized as broadly toxic were evaluated in the concentration 
range of 10 nM – 5 µM (10 nM, 50 nM, 100 nM, 250 nM, 500 nM, 1 μM, 5 μM). The top 
candidate compound was evaluated in combination with the other candidate compounds at 
concentrations ranging from 50 nM – 5 μM (50 nM, 100 nM, 250 nM, 500 nM, 1 μM, 5 
μM). Combination studies followed the same protocol as single compound screening. Cells 
were incubated for 24 hours prior to ATP luminescence assays. Synergy between 
combinations was assessed by the Bliss independence model and Chou-Talalay 
combination index (CI) [157, 158]. In conjunction with cell viability, these mathematical 
methods were used to identify the most effective and synergistic combination for 
metabolomics analysis. Bliss values were calculated within the R programming 
environment [159]. Chou-Talalay CI values were calculated with CompuSyn [160].  
2.3.5 Ultrahigh performance liquid chromatography-mass spectrometry (UPLC-
MS) analysis 
Following the identification of the most synergistic combination, metabolomics 
analysis was performed. RCH-ACV and Reh cell lines were chosen for metabolomics 
analysis because they most closely mimicked the response of patient-derived cells. Cells 
were seeded in 6-well plates (Corning Incorporated, Corning, NY, USA) in triplicate. Four 
groups were assessed: vehicle control, DMAPT, SHK, and combination. This experiment 
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was performed under three different labeling conditions: unlabeled glucose and glutamine, 
13C6-glucose and unlabeled glutamine, or unlabeled glucose and 13C5,15N2-glutamine. 
Following a 24-hour treatment period, cells were aspirated, washed with phosphate 
buffered solution, harvested by centrifugation, and snap frozen in liquid nitrogen. 
Metabolite extraction was performed by modified Bligh-Dyer, similar to previously 
reported [138]. In brief, cell pellets were extracted with 1:1 water:methanol with 10 mM 
ammonium bicarbonate and equal parts chloroform. BHT was added to the extraction 
buffer to preserve metabolites susceptible to oxidation.  
The polar fractions were transferred to LC-MS vials for immediate analysis. 
Metabolite extracts were spiked with a mixture of deuterated internal standards (IS) to 
monitor retention time, ionization efficiency, and instrument stability. Chromatographic 
separation was achieved on an Accela 1250 UPLC system equipped with a quaternary 
pump, vacuum degasser, and an open autosampler with temperature controller (6°C, Fisher 
Scientific, San Jose, CA, USA) coupled to a UPLC column. First, a SeQuant ZIC-HILIC 
3.5 μm, 100 Å, 150 x 2.1 mm PEEK coated HPLC column (Millipore Sigma, Burlington, 
MA, USA) was used to analyze redox cofactors. Mobile phase A was 10 mM ammonium 
acetate in water and mobile phase B was acetonitrile. An isocratic separation was 
performed at a flow rate of 150 μL/min with 90% A and 10% B for 12 minutes with an 
injection volume of 4 µL. Second, a Synergi 4 µm Hydro-RP 80 Å, 150 x 2 mm HPLC 
column (Phenomenex, Torrance, CA, USA) was used for additional polar metabolites. 
Mobile phase A was water with 0.2% formic acid and mobile phase B was methanol. A 
gradient separation was performed holding 1% B for 2 minutes, then linear 30-80% B in 8 
minutes, washing with 98% B for 5 minutes, and column equilibration with 1% B for 15 
minutes. The total run time was 30 minutes with a flow rate of 250 µL/min and an injection 
volume of 5 µL. In both cases, eluent was coupled to a Q Exactive Hybrid Quadrupole 
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Orbitrap mass spectrometer with an electrospray ionization (ESI) source simultaneously 
operating in fast negative/positive ion switching mode (Thermo Scientific, Bremen, 
Germany). The following acquisition settings were used for data collection in full MS 
mode: spray voltage, 3.5 kV; capillary temperature, 320°C; sheath gas, 45 (arbitrary units); 
auxiliary gas, 10 (arbitrary units); m/z range, 70-1000 (HILIC), 50-750 (RP); data 
acquisition, centroid mode; microscans, 10; AGC target, 1e6; maximum injection time, 
200 ms; mass resolution, 70,000 FWHM at m/z 200. Accuracy of MS analysis was ensured 
by calibrating the detector prior to analysis. Non-polar fractions were evaporated to dryness 
in a CentriVap refrigerated vacuum concentrator (Labconco, Kansas City, MO, USA) at 
4°C. Metabolites were subsequently resuspended in 95:5 ethanol:6N HCl for analysis. 
Chromatographic separation was achieved with a Kinetex 2.6 µm C18 100 Å, 150 x 2.1 mm 
column (Phenomenex, Torrance, CA, USA) running at a flow rate of 260 µL/min of 60:40 
2-propanol:methanol with 5 mM ammonium formate for 4 minutes and a 5 µL injection 
volume, as previously reported [161]. Eluent was coupled to the instrumentation above. 
Acquisition parameters for full MS/AIF were as follows: ionization mode, positive; spray 
voltage, 4.0 kV; capillary temperature, 300°C; sheath gas, 50 (arbitrary units); auxiliary 
gas, 10 (arbitrary units); m/z range, 150-1000; data acquisition, centroid mode; microscans, 
1; AGC target, 1e6/5e5; maximum injection time, 200 ms; mass resolution, 140,000/70,000 
FWHM at m/z 200; higher energy collisional dissociation (HCD), 22 eV. Mass tolerance 
was maintained at 5 ppm for all analyses. 
The UPLC-MS analytical platform was controlled by a computer operating the 
Xcalibur v. 2.2 SP1.48 software package (Thermo Scientific, San Jose, CA, USA). Raw 
files were processed using SIEVE 2.2.0 SP2 (Thermo Scientific, San Jose, CA, USA) and 
an in-house script that operates in the MATLAB programming environment. Spectral 
alignment and peak picking were performed in SIEVE. Integrated intensities, monoisotopic 
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masses, and retention times were exported for further analysis. In MATLAB, metabolite 
identifications were determined by matching accurate masses and retention times to a mass 
spectral metabolite library of standards. A pooled quality control (QC) was used to monitor 
instrument stability and a blank was used for background subtraction. Peaks were included 
in analysis if the coefficient of variance (CV) was <0.25 and >0 in the QC replicates. 
Probabilistic quotient normalization (PQN) was performed prior to statistical analysis 
[162]. Pathway analysis was performed with MetaboAnalyst on confirmed features [163].  
 
2.4 RESULTS  
2.4.1 Natural product library (NPL) screening 
An NPL composed of 136 unique compounds (Table A1) was assessed for 
cytotoxicity (measured by ATP luminescence) in 12 cell populations (Summary in Table 
2.1). Normal cells were used to evaluate the specificity of cytotoxic compounds for cancer 
cells. Cells were treated with a 10 µM final concentration for 12, 24, and 48 hours. Overall, 
time course data showed that 12 hours was too early to see persistent effects on cell viability 
and 48 hours was too long to differentiate the effects of cytotoxic compounds (data not 
shown). Therefore, 24 hours was selected as indicative of robust cytotoxicity.  
Seven compounds resulted in viability inhibition of >25% in leukemia cells derived 
from patients: 10-hydroxycamptothecin, cyclocytidine, dioscin, parthenolide, shikonin, 
tetrandrine, and triptolide (Figure 2.1A). Interestingly, immortalized BCP-ALL cells were 
sensitive to a greater number of compounds, with an additional 21 achieving >25% 
viability inhibition (Figure 2.1B) . In vitro experiments can overestimate the anti-cancer 
activities of compounds leading to poor clinical outcomes [164]. Thus, the inherent 
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resistance of primary cells was used as a guide. Only compounds considered effective in 
primary BCP-ALL cells were evaluated further. 
   To assess specificity for cancer cells, viability inhibition of leukemia versus normal 
cells was plotted for all 136 compounds (Figure 2.1). Of the seven compounds considered 
cytotoxic in primary leukemia cells, dioscin, shikonin, and tetrandrine inhibited normal 
cell viability above 50% suggesting the concentration should be reduced in subsequent 
experiments. These compounds were classified as broadly toxic at 10 µM. Conversely, 10-
hydroxycamptothecin, cyclocytidine, parthenolide, and triptolide were less toxic to normal 





Figure 2.1: Growth inhibition patterns in BCP-ALL compared to normal indicate 
similar trends in compound efficacy 
Compounds that inhibited primary cell growth (A) by more than 25% were comparably 
effective in immortalized cell lines (B). Compounds with an average growth inhibition 
above 50% were considered cytotoxic at 10 µM. Compounds that demonstrated less than 
50% growth inhibition in normal cells while exhibiting efficacy in malignant populations 
were considered selective for leukemia cells. Growth inhibition was calculated from ATP 
luminescence. BCP-ALL, precursor B-cell acute lymphoblastic leukemia.  
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The difference in viability between leukemia and normal cells was calculated for 
the seven candidate compounds. Parthenolide (PTL) achieved the greatest average 
difference in both primary and immortalized cells. PTL growth inhibition was <20% in 
normal cells and >70% in primary malignant cells. In immortalized leukemia cells, the 
difference was even greater with PTL achieving >80% growth inhibition. Thus, PTL was 
selected as the leading candidate compound due to its high efficacy in primary and 
immortalized leukemia cells coupled with exceptionally low toxicity in normal cells. For 
each combination, a range of concentrations was evaluated to assess synergy. 
Concentration ranges were 50 nM – 5 μM (6 concentrations) for PTL, 10 nM – 5 μM (7 
concentrations) for broadly toxic compounds, and 250 nM – 15 µM (7 concentrations) for 
selectively toxic compounds. In total, 42 combinations were assessed for each of the six 
compounds evaluated in combination with PTL.  
The Bliss independence model was used to evaluate synergy for each compound 
and concentration pair. In the Bliss model, negative values indicate antagonism, zero 
implies an additive effect, and positive values denote synergism [157]. High confidence 
values were defined as ≥0.1, thus strongly indicative of synergism. Of the six compounds 
analyzed in combination with PTL, all but triptolide demonstrated some level of synergism 
in BCP-ALL (Table A2). Tetrandrine and 10-hydroxycamptothecin both had a small 
number of synergistic combinations, but neither were observed across all leukemia cells. 
Shikonin and dioscin resulted in synergistic combinations with PTL at several 
concentrations in all leukemia cells. In general, synergism between PTL and shikonin was 
higher in magnitude and frequency than PTL and dioscin. Consequently, the combination 
of PTL and shikonin (SHK) was selected for further evaluation. The synergy between PTL 
and SHK increased with increasing concentrations of both compounds and peaked between 
750 nM – 1 µM PTL and 500 nM – 1 µM SHK (Figure 2.2A). At concentrations >1 µM, 
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synergy dropped precipitously, likely due to high cytotoxicity in some cells. The maximum 
Bliss values for Reh and NALM-6 were observed at 1 µM PTL:SHK. RCH-ACV was the 
most resistant cell line with a maximum Bliss index at 5 µM dose for each compound. 
However, concentrations this high were not found to be synergistic in other cell line. 
KOPN-8 was particularly sensitive to SHK with a maximum Bliss value at 1 µM:250 nM 
PTL:SHK. Nonetheless, the maximal Bliss index was only marginally higher than at 1 µM 
PTL:SHK. Kasumi-2 cells were the most sensitive to both PTL and SHK with a maximum 
Bliss value at 750 nM:100 nM PTL:SHK. This combination was not synergistic in any 
other cell line. Similar to KOPN-8, synergism decreased but was not lost at 1 µM each in 
Kasumi-2 (Figure 2.2A, Table A2). Consistent with the results of single compound 
screening, primary cells were more resistant to the combinations than immortalized cell 
lines. Importantly, in normal cells there were no discernible patterns of synergism 
indicating leukemia-specific activity. Taken together these data suggest that 1 µM 
PTL:SHK would be strongly synergistic across pediatric BCP-ALL cells without 




Figure 2.2: Bliss independence model determination of the most synergistic 
combination of parthenolide and dimethylaminoparthenolide with shikonin 
(A) Viability inhibition and Bliss indices were calculated for each combination of PTL and 
SHK in immortalized and primary cells. Subplots exhibit shifting efficacy and synergy 
across concentrations and compound ratios. Bliss indices for tertiary screening of 1:1 ratio 
of the synthetic PTL analog DMAPT and SHK visualized as surface plots indicate maximal 
synergy near 1 µM DMAPT:SHK in RCH-ACV (B) and Reh (C) cells. PTL, parthenolide; 
DMAPT, dimethylaminoparthenolide, SHK, shikonin. 
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PTL is known to have limited bioavailability in vivo, a clinical application 
challenge for many natural products. An orally bioavailable analog was previously 
developed to overcome this limitation [165]. DMAPT has been shown to have improved 
water solubility (1000-fold) and bioavailability, as well as, comparable chemical 
specificity and in vitro efficacy as PTL [165, 166]. Our analysis confirmed that DMAPT 
and PTL demonstrated comparable activity in BCP-ALL and normal cells (Figure B1). 
The combination of 1 µM DMAPT:SHK also exhibited minimal toxicity in normal cells 
(data not shown). To confirm synergism observed in PTL and SHK was also maintained 
with DMAPT, a final round of screening was performed with 1:1 DMAPT:SHK ranging 
from 50 nM – 5 µM. Bliss indices exhibited similar synergism to PTL (Figure 2.2B, C). 
Additionally, the Chou-Talalay CI was calculated for this combination. For Chou-Talalay, 
CI >1 denotes antagonism, CI equal to one indicates an additive effect, and CI <1 one 
represents synergism. The CI for RCH-ACV was 0.90102 for 1:1 DMAPT:SHK at 1 µM 
each. The CI for Reh was 0.34616 for the same concentration. Interestingly, in this model 
increasing the dose beyond 1 µM each was predicted to shift towards antagonism in RCH-
ACV cells. The synergistic window spanned from 0.1 to 0.6 Fa (fraction affected) (Figure 
B2A, B). In Reh cells, the CI was predicted to decrease steadily with dose escalation 
indicating no upper limit to the synergistic effect (Figure B2C, D). Based on the combined 
results of the Bliss independence model and the Chou-Talalay CI, 1 µM:1 µM 
DMAPT:SHK was selected for further investigation. 
2.4.2 Metabolomics and metabolic flux analysis 
Following the selection of DMAPT:SHK as the top synergistic combination, 
metabolomics analysis was performed. Reh and RCH-ACV cell lines most closely 
mirrored the viability inhibition and synergistic compound sensitivity of primary cells in 
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both single and combination screening. As such, they were chosen for metabolomics 
experiments to best recapitulate the response of primary BCP-ALL cells. Similar to 
screening conditions, cells were incubated for 24 hours with 1 µM DMAPT, SHK, or both. 
Intracellular profiles were analyzed by ultrahigh performance liquid chromatography-mass 
spectrometry (UPLC-MS). Features extracted from UPLC-MS analyses were matched to a 
mass spectral metabolite library of standards containing accurate masses and 
chromatographic retention times. This resulted in the positive identification of 83 and 81 
metabolites confirmed in all treatment groups in RCH-ACV and Reh cells, respectively. 
Fold-change (FC) was calculated relative to vehicle control for DMAPT, SHK, and the 
combination (Figure 2.3). Several metabolites involved in energy metabolism and 
proliferation were reduced in the combination group relative to control. In addition, 
pathway analysis was performed to contextualize the results of UPLC-MS analysis (RCH-
ACV, Table 2.2; Reh, Table 2.3). These results quantified the significance of the DMAPT, 
SHK, and DMAPT:SHK on intracellular metabolism. Single treatment with DMAPT did 
not result in any statistically significant pathways (calculated by FDR q-value) with an 
impact greater than 0.2 or that included ≥10 annotated metabolites. SHK alone did not 
result in any significant pathways in Reh cells. In RCH-ACV cells, single treatment with 
SHK was less remarkable than the combination, but nonetheless resulted in significant q-
values (q <0.01). Specifically, alanine, aspartate, and glutamate metabolism, taurine and 
hypotaurine metabolism, glutathione metabolism, and the TCA cycle (tricarboxylic acid 
cycle) were significantly changed (Table 2.2). For the combination, statistically significant 
pathways with the greatest impact fell under four major categories: (1) amino acid 
metabolism (of which the top three were alanine, aspartate, and glutamate metabolism, 
arginine and proline metabolism, and glycine, serine, and threonine metabolism), (2) 
antioxidant metabolism (taurine and hypotaurine metabolism, glutathione metabolism), (3) 
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the TCA cycle, and (4) nucleotide metabolism (pyrimidine metabolism, purine metabolism) 
(Tables 2.2, 2.3).  
Many amino acids were significantly decreased in the combination group. Notably, 
glutamine, an important oncogenic substrate[61], was not decreased in the combination 
group in either cell line. Intracellular glutamine was not statistically significant between 
treatments in RCH-ACV cells. In contrast, glutamine was significantly reduced in single 
treatments, but not the combination in Reh cells. Interestingly, the antioxidant tripeptide, 
glutathione was not significantly different between groups despite decreased glycine, 
cysteine, and glutamate. Taurine and hypotaurine, which are also potent antioxidants, were 
significantly reduced in the combination. The significance of glutathione metabolism and 
taurine and hypotaurine metabolism suggest oxidative stress following treatment with 
DMAPT:SHK. Along these lines, redox cofactors including coenzyme Q10 (ubiquinone) 
indicated a cellular environment with high reactive oxygen species (ROS). The ratio of 
oxidized (CoQ10) to reduced (CoQ10H2, ubiquinol) coenzyme Q was elevated following 
treatment, especially in RCH-ACV cells (Table 2.4). 
In the combination group, there was an appreciable difference between RCH-ACV 
and Reh cells regarding pathway q-values for the TCA cycle. This pathway was highly 
significant in RCH-ACV (q = 0.0024) but not statistically significant in Reh (q = 0.8733) 
cells. Consistent with this, most TCA cycle intermediates trended in the same direction 
with the combination being most significantly decreased in RCH-ACV cells. In contrast, 
none of the TCA cycle intermediates were statistically significant in the combination in 
Reh cells. Rather, citrate, malate, and fumarate were more depressed following single 
compound treatment.  
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Figure 2.3: Modulation of unique metabolites demonstrates global changes in cellular 
metabolism following treatment with DMAPT, SHK, or both 
Metabolites extracted from (A) RCH-ACV and (B) Reh leukemia cell lines are expressed 
in fold change (FC) compared to vehicle control as measured by UPLC-MS of intracellular 
extracts following 24-hour treatment. Hierarchical clustering was performed by Euclidean 
distance and average linkage methods. DMAPT, Dimethylaminoparthenolide; SHK, 
Shikonin; COMBO, combination. 
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Table 2.2: Metabolic pathway analysis in RCH-ACV cells  
Pathway analysis was performed on UPLC-MS features positively identified by accurate 
mass and retention time. Hits indicates the number of identified compounds over the total 
number of compounds in the specified pathway. Pathways were included if the impact was 
>0.2 and/or ≥10 annotated compounds. FDR q-values <0.01 are in bold. UPLC-MS, 
ultrahigh performance liquid chromatography-mass spectrometry; DMAPT, 
dimethylaminoparthenolide; SHK, shikonin; TCA cycle, tricarboxylic acid cycle. 
 
Pathway Hits Impact DMAPT SHK Combination 
Alanine, aspartate, and glutamate metabolism 8/24 0.7540 0.9859 0.0017 0.0021 
Arginine and proline metabolism 17/77 0.6381 0.9859 0.0107 0.0025 
Glycine, serine, and threonine metabolism 11/48 0.4693 0.9859 0.0115 0.0021 
Taurine and hypotaurine metabolism 4/20 0.4443 0.9859 0.0037 0.0052 
Glutathione metabolism 11/38 0.4343 0.9859 0.0038 0.0067 
Pyrimidine metabolism 10/60 0.2944 0.9859 0.0563 0.0062 
Histidine metabolism 8/44 0.2604 0.9859 0.0107 0.0006 
Pantothenate and CoA biosynthesis 7/27 0.2447 0.9859 0.0102 0.0062 
TCA cycle 6/20 0.2386 0.9859 0.0017 0.0024 
Aminoacyl-tRNA biosynthesis 19/75 0.2254 0.9859 0.0107 0.0024 
Glycerolipid metabolism 3/32 0.2162 0.9859 0.7258 0.5619 
Purine metabolism 15/92 0.2050 0.9859 0.0107 0.0047 
Biotin metabolism 2/11 0.2033 0.9859 0.0219 0.0046 
Nitrogen metabolism 11/39 0.0083 0.9859 0.0285 0.0024 
 
Table 2.3: Metabolic pathway analysis in Reh cells 
Pathway analysis was performed on UPLC-MS features positively identified by accurate 
mass and retention time. Hits indicates the number of identified compounds over the total 
number of compounds in the specified pathway. Pathways were included if the impact was 
>0.2 and/or ≥10 annotated compounds. FDR q-values <0.01 are in bold. UPLC-MS, 
ultrahigh performance liquid chromatography-mass spectrometry; DMAPT, 
dimethylaminoparthenolide; SHK, shikonin; TCA cycle, tricarboxylic acid cycle. 
 
Pathway Hits Impact DMAPT SHK Combination 
Alanine, aspartate, and glutamate metabolism 9/24 0.7778 0.4039 0.4039 0.0260 
Arginine and proline metabolism 16/77 0.6166 0.4039 0.4039 0.0015 
Taurine and hypotaurine metabolism 5/20 0.5414 0.5173 0.5173 0.0077 
Glycine, serine, and threonine metabolism 9/48 0.4636 0.5173 0.5173 0.0003 
Glutathione metabolism 10/38 0.3474 0.4039 0.4039 0.0067 
Pyrimidine metabolism 10/60 0.2814 0.4039 0.4039 0.0006 
TCA cycle 6/20 0.2386 0.4039 0.4039 0.8733 
Aminoacyl-tRNA biosynthesis 19/75 0.2254 0.4548 0.4548 0.0006 
Histidine metabolism 8/44 0.2115 0.4271 0.4271 0.0026 
Biotin metabolism 2/11 0.2033 0.4039 0.4039 0.0003 
Lysine degradation 5/47 0.2025 0.4271 0.4271 0.0026 
Purine metabolism 16/92 0.1962 0.4039 0.4039 0.0029 
Nitrogen metabolism 13/39 0.0998 0.4271 0.4271 0.0008 
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Table 2.4: Redox cofactor ratios indicate mitochondrial dysfunction following 
treatment 
NAD+ captures energy released from biological processes as NADH and transfers it to the 
electron transport chain (ETC) for ATP synthesis. Coenzyme Q10 is an electron carrier in 
the ETC. Electrons are transferred from NADH to generate reduced coenzyme Q10H2. 
Depletion of NADH and CoQH2 are indicative of reduced oxidative phosphorylation and 
elevated oxidative stress. p-values <0.05 are in bold. Con, control; DMAPT, 
dimethylaminoparthenolide; SHK, shikonin; Comb, combination; ND, not detected. 
 
RCH-ACV Reh 
Cofactor Ratio Con DMAPT SHK Comb Con DMAPT SHK Comb 
[CoQ10]/[CoQ10H2] 12 15 22 24 9 8 12 9 
[NAD+]/[NADH] 34 35 ND ND 15 12 48 39 
 
Lastly, nucleotide metabolism was most significantly reduced in the combination. 
Q-values for pyrimidine metabolism and purine metabolism were 0.0062 and 0.0042, 
respectively, for RCH-ACV cells. Similarly, in Reh cells, the q-values were 0.0006 and 
0.0029 for pyrimidine and purine metabolism, respectively. Treatment with DMAPT:SHK 
resulted in a consistent reduction in nucleotide mono-, di-, and triphosphates. Nucleosides, 
nitrogenous bases, and amino acids required for nucleotide synthesis were not as clearly 
clustered but were generally decreased in the combination as well. 
 To elucidate the mechanisms of these changes, MFA was performed with 13C6-
glucose and 13C5,15N2-glutamine (Figure 2.4). The DMAPT:SHK combination reduced 
overall glucose utilization, but glucose-derived 13C incorporation was not significantly 
different in glycolysis or the TCA cycle. In the combination group, a small increase in label 
incorporation was observed for some metabolites in RCH-ACV, but consistent with the 
unlabeled data, this was not observed in Reh cells. The most pronounced difference in 
glucose label incorporation was the shunting of 13C-labeled sugars (predominantly M+5) 
into nucleotide synthesis through the pentose phosphate pathway (PPP). Label 
incorporation in nucleotide metabolism was significantly decreased by the combination, 
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most substantially in pyrimidine synthesis. Glutamine incorporation differed greatly 
between RCH-ACV and Reh cells. Leukemia cells typically divert glutamine towards 
biosynthetic and energy production pathways via glutaminolysis, first converting 
glutamine to glutamate and then to α-ketoglutarate which can enter the TCA cycle. In RCH-
ACV cells, treatment with the combination (and SHK alone) diminished the conversion of 
glutamine to glutamate. This was propagated downstream in the TCA cycle seen through 
the reduction of label incorporation in fumarate and malate as well as a reduction in 
aspartate (synthesized from the TCA cycle intermediate oxaloacetate). Incorporation of 13C 
and 15N from glutamine was most significantly diminished in purine and pyrimidine 
nucleotides. In contrast, asparagine synthesis, which also utilizes carbon and nitrogen from 
aspartate was not affected in any group. No significant difference in TCA cycle 
intermediates was observed in Reh cells treated with the combination. Nonetheless, at the 
level of pyrimidine synthesis there was a substantial decrease in label incorporation 
suggesting an inhibitory mechanism downstream from aspartate in these cells. These 
results are consistent with pathway analysis which indicated that alanine, aspartate, and 
glutamate metabolism and the TCA cycle were not significantly changed in Reh cells but 
were significantly different in RCH-ACV cells. In addition to the canonical oxidative TCA 
cycle metabolism, the reductive flux of 13C-labeled carbon was observed in RCH-ACV 
cells. Glutamine-derived label incorporation from reductive flux was observed in citrate, 
aspartate, malate, and the oncometabolite 2-hydroxyglutarate [167].  
 42 
 
Figure 2.4: DMAPT and SHK induce changes in intracellular glucose and glutamine 
flux in precursor B-cell leukemia  
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Figure 2.4: DMAPT and SHK induce changes in intracellular glucose and glutamine 
flux in precursor B-cell leukemia, continued  
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Figure 2.4: DMAPT and SHK induce changes in intracellular glucose and glutamine 
flux in precursor B-cell leukemia, continued 
(A) RCH-ACV and (B) Reh cells were cultured in medium containing 13C6-glucose or 
13C5,15N2-glutamine and treated with vehicle, DMAPT, SHK, or both. Stable isotope 
enrichment is shown as a fraction of the total metabolite pool averaged over three 
replicates. Glc, 13C6-glucose; Gln, 13C5,15N2-glutamine; CON, vehicle control; DMAPT, 
dimethylaminoparthenolide; SHK, shikonin; COMBO, combination; G3P, glyceraldehyde 
3-phosphate; DHAP, dihydroxyacetone phosphate; 1,3-BPG, 1,3-bisphosphoglyceric acid; 
2-HG, 2-hydroxyglutarate; UMP, uridine monophosphate; ATP, adenosine triphosphate; 
PPP, pentose phosphate pathway; TCA cycle, tricarboxylic acid cycle. 
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2.5 DISCUSSION 
In this study, a library of natural products was screened for cytotoxicity in BCP-
ALL and normal bone marrow-derived cells. Most chemotherapeutics are broadly toxic to 
cancer and normal cells alike, which leads to short- and long-term consequences for 
patients, especially very young ones [34, 140]. Thus, differences in BCP-ALL and normal 
cells viability were critical for identifying compounds that exhibited selective activity in 
leukemia cells. The effect of each NPL compound on cell viability was monitored by ATP 
luminescence. Intracellular ATP is essential for cancer cell survival and depletion has been 
linked to apoptosis in a number of cancer cells [168]. Furthermore, SHK has previously 
been shown to decrease ATP and lead to cell death in hepatocellular carcinoma and 
melanoma [169, 170]. The first round of screening resulted in seven candidate compounds, 
with PTL having the greatest difference in viability between normal and BCP-ALL cells. 
A secondary screen was performed combining PTL with the six other candidate 
compounds to investigate synergistic combinations. Bliss indices narrowed the candidate 
pool to PTL and SHK. Importantly, normal cells we equally unaffected by the synergistic 
combination indicating that leukemia cell specificity was maintained with PTL and SHK. 
PTL has been shown to be effective against acute leukemias but has limited 
solubility and bioavailability [171, 172]. To ameliorate this limitation, an orally 
bioavailable, water-soluble analog (DMAPT) was developed previously and found to 
induce cell death in acute myeloid leukemia cells [165, 166]. This study demonstrated that 
PTL and DMAPT also have comparable activity in BCP-ALL. Next, DMAPT was 
evaluated in combination with SHK to confirm comparable synergism to PTL and SHK. 
Evaluation by two methods, Bliss and Chou-Talalay, indicated synergy between DMAPT 
and SHK near maximal at 1 µM DMAPT:SHK for both cell lines. Subsequent experiments 
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were performed under these conditions to elucidate the metabolic consequences of 
DMAPT:SHK treatment.  
Metabolomics analysis revealed a significant impact on global metabolite levels in 
single and combination groups. Metabolites central to sustaining the energetic and 
biosynthetic needs of leukemia cells were modulated by DMAPT, SHK, and the 
combination. Pathway analysis confirmed that amino acid, antioxidant, TCA cycle (in 
RCH-ACV cells), and nucleotide metabolism were central to the biological effects of the 
combination. MFA with 13C6-glucose revealed a limited influence on the incorporation of 
glucose in glycolysis or the TCA cycle. Overall, glycolysis and the TCA cycle were 
downregulated, but label incorporation was uniform. Instead, treatment resulted in a 
significant decrease in 13C-label incorporation into nucleotides, particularly in the 
combination and SHK alone. SHK has been shown to inhibit PKM2 (pyruvate kinase M2) 
which is key in diverting glucose into PPP [169]. Inhibition of PKM2 leads to suppression 
of metabolism, decreased proliferation, and ultimately apoptosis [173, 174]. Label 
incorporation from 13C5,15N2-glutamine differed between cell lines. In RCH-ACV cells, the 
combination group (and SHK alone) had reduced label incorporation that propagated from 
glutamine through glutaminolysis, the TCA cycle, and nucleotide synthesis. The net effect 
of these pathways is both energy generation and biosynthesis of macromolecules for 
proliferation. DMAPT has been shown to directly inhibit cell survival and proliferative 
signals from NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) [166, 
171], STAT (signal transducer and activator of transcription) [175], and MAPK (mitogen-
activated protein kinases) [176]. At the same time, DMAPT activates pro-apoptotic 
signaling through JNK (c-Jun N-terminal kinases) and p53 [165, 166, 177]. This 
simultaneous shifting of metabolism away from pro-survival and proliferative signals was 
seen via reduced biosynthetic label incorporation, most remarkably in nucleotides. 
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Reductive flux through the TCA cycle was also limited as seen by diminished label 
incorporation (M+5, M+3) 2-hydroxyglutarate, citrate, aspartate, and malate. In Reh cells, 
minimal differences in label incorporation in the TCA cycle were seen between groups. 
Consistent with the unlabeled data, DMAPT and SHK appear to have a greater impact 
individually on TCA cycle intermediates. Although no difference was observed in TCA 
cycle flux, the significant reduction in nucleotide synthesis was similarly observed in Reh 
cells, suggesting an inhibitory mechanism further downstream. Other studies have also 
shown a stronger response in purine and pyrimidine metabolism than other pathways in 
response to metabolic stress [178]. Synergism between DMAPT and SHK may be 
explained by inhibition of the PI3K/AKT/mTOR (phosphoinositide 3-kinase/protein 
kinase B, mammalian target of rapamycin) signaling cascade by SHK. mTOR regulates 
cancer cell anabolism and drives nucleotide synthesis for ribosome biogenesis and DNA 
synthesis. Inhibition of this process leads to the depletion of nucleotides, DNA damage, 
and selective cytotoxicity [179]. Furthermore, DMAPT has been shown to be synergistic 
with mTOR inhibitors in acute myeloid leukemia [180, 181]. Thus, despite minimal 
differences in energy metabolism, biosynthetic pathways central to leukemia cell survival 
were nonetheless significantly inhibited resulting in arrested proliferation and ultimately 
cell death.  
In this study, successive rounds of compound screenings led to the identification of 
a synergistic combination of natural products that exhibited strong effects on BCP-ALL 
cell viability with minimal consequences in normal cells. DMAPT and SHK altered total 
metabolite pools and inhibited flux through key pathways involving amino acids, 
antioxidants, the TCA cycle, and nucleotides. Together DMAPT and SHK exploited the 
metabolic vulnerabilities of BCP-ALL. This combination indicates a promising avenue for 
BCP-ALL treatment with less toxic, leukemia-specific treatments. To assess clinical 
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applicability, future studies could evaluate DMAPT and SHK in combination with standard 
and reduced doses of current therapeutics. 
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Chapter 3: Stratification of pediatric leukemia patients by combining 
clinical parameters and metabolic signatures to identify exploitable 
pathway dysregulation for a personalized therapeutic approach 
3.1 ABSTRACT 
Cytogenetic analyses have revealed that most pediatric precursor B-cell acute 
lymphoblastic leukemia (BCP-ALL) cells possess gross chromosomal alterations, many of 
which have been correlated with patient outcomes. Aberrations in the IGH locus have been 
associated with poor prognosis in pediatric patients, likely due to the frequency of 
oncogene translocations into proximity of the IGH promotor. Yet, little is known about the 
phenotypic consequences of these mutations. Chromosomal anomalies have a significant 
effect on both cancer phenotype and response to therapeutics. Here, we utilized a 
metabolomics approach to characterize the global metabolic effects of genetic aberrations 
at the IGH locus. This study investigated the relationship between traditional clinical 
markers, cytogenetics, and intracellular metabolite profiles in pediatric leukemia patients 
at diagnosis. Metabolites extracted from fresh bone marrow (BM) aspirates of 41 BCP-
ALL patients were analyzed by ultrahigh performance liquid chromatography-mass 
spectrometry (UPLC-MS). Multivariate analysis demonstrated that global metabolic 
profiles were significantly altered by anomalies at the IGH locus. We observed unique 
metabolic profiles suggesting dysregulation of several major pathways when patients were 
stratified by their primary cytogenetic anomalies. Assessment of individual metabolites 
indicated nucleotides and energy metabolism intermediates were decreased in the BM of 
patients with IGH anomalies. Conversely, levels of amino acids, amino acid-related 
metabolites, and some sugars were increased in these patients. Phosphatidylcholines, 
phosphatidylethanolamines, and polar metabolites involved in lipid transport and 
metabolism were also increased in IGH mutants. These data suggest that aberrations at the 
 50 
IGH locus result in characteristic dysregulation of central metabolic pathways involving 
both polar metabolites and lipids. Screening of a cancer compound library in BCP-ALL 
cells harboring an IGH locus aberration indicated that therapeutics targeting heat shock 
protein, proteasome, mTOR, and HDAC activities is an effective strategy for inhibiting 
leukemia cell proliferation. Interrogation of metabolic dysregulation and the identification 
of novel therapeutics is a promising step towards personalized treatment for patients 
carrying this mutation, an essential development for improving the quality of life and long-
term outcomes of pediatric leukemia patients.  
 
3.2 INTRODUCTION 
Cancer is the leading cause of disease-related death in children and adolescents ages 
1–19 years [1, 26]. Leukemia is the most common pediatric cancer, accounting for 28% of 
all cancers in children [1, 19]. Current treatment strategies involve a very intense, risk-
directed induction phase at the outset of treatment followed by a series of consolidation, 
intensification, and maintenance therapies that typically spans 2–3 years [15, 27, 49, 139]. 
This approach effectively induces remission in most patients but is highly toxic and 
consequently results in significant short- and long-term side effects [34-40, 140]. Among 
childhood leukemia survivors, 75% report a least one chronic condition 5–14 years post-
diagnosis, a figure that climbs to 85% by 25–36 years [141]. Even more staggering, when 
evaluated clinically, 98.2% of long-term survivors were diagnosed with at least one chronic 
health condition [21]. Patient outcomes have improved as a result of optimization of current 
treatment protocols in recent decades [1]. In particular, risk-directed treatment 
incorporating minimal residual disease (MRD) and cytogenetic anomalies that correlate 
with prognosis have greatly improved patient stratification [15, 40, 42, 47].  
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There is a significant amount of genetic diversity in BCP-ALL [182]. Many 
recurrent cytogenetic anomalies in BCP-ALL have been shown to correlate with patient 
outcomes [15, 17, 48, 183-190]. The World Health Organization (WHO) recognizes seven 
established BCP-ALL cytogenetic subtypes: t(9;22)(q34.1;q11.2)/BCR-ABL1, 
t(12;21)(p13.2;q22.1)/ETV6-RUNX1, t(v;11q23.3)/KMT2A rearranged (previously MLL 
translocations), t(1;19)(q23;p13.3)/TCF-PBX1, t(5;14)(q31.1;q32.3)/IGH@-IL3, and high 
hyperdiploidy (HeH), hypodiploidy, and two provisional subtypes: BCR-ABL1-like and 
iAMP21 [47, 182]. In BCP-ALL, two anomalies have consistently been associated with 
high rates of remission and 5-year relative survival, hyperdiploidy and ETV6-RUNX1 
translocation. The definition of HeH varies with research protocol, but the two most 
common definitions are the gain of five or more chromosomes (51+) or the specific gain 
of chromosomes 4 and 10 (or 4, 10, and 17). Inversely, hypodiploidy, typically defined as 
fewer than 40 chromosomes, is associated with poor prognosis. Patients with MLL 
translocations are also considered high risk and individuals with this anomaly are 
predominantly less than one year old [15, 40, 42, 47, 48]. Likewise, patients carrying the 
BCR-ABL1 mutation are considered very high risk and assigned to a separate protocol that 
utilizes tyrosine kinase inhibitors (TKI) [191-193]. However, less than half of the recurrent 
chromosomal anomalies that have been correlated with clinical outcomes are presently 
used clinically for patient stratification and risk-directed treatment. There is a growing 
body of evidence that suggests chromosomal anomalies beyond the classifications 
recognized by the WHO represent important clinical markers as well as potential targets 
for novel therapeutics [42, 194]. 
While most chromosomal aberrations occur with high fidelity, likely due to 
chromatin structure, translocations at the IGH locus are quite promiscuous [44, 184, 195-
198]. Translocation and other anomalies at the IGH locus result in bringing target genes 
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into proximity of the IGH enhancer region, thus resulting in dysregulation of genes 
downstream of IGH [184, 195, 196, 199-202]. Aberrations at the IGH locus, located on 
chromosome 14, occur at varying rates depending on patient age [42, 48]. Different 
anomalies are common at this locus including translocations, separations, insertions, 
deletions, and copy number variants. Despite the promiscuity of the IGH locus, 
translocation partners are not random. In BCP-ALL, the IGH locus has several recurrent 
partner genes including: MYC, CRLF2, BCL-2, ID4, EPOR, IL3, IGF2BP1, and CEBP 
family members [44, 47, 185, 197, 203-208]. These genes serve several purposes and are 
broadly involved in cell cycle regulation, apoptosis evasion, proliferation, differentiation, 
immunity, and metabolism. Aberrations at the IGH locus have been associated with poor 
prognosis in pediatric patients, but little is known of the phenotypic consequences of these 
mutations [44, 184, 201, 209, 210]. 
While cytogenetics has provided important information about chromosomal 
aberrations and oncogenes, it has failed to fully explain the biological consequences of 
many anomalies. In fact, one of the biggest challenges to incorporating cytogenetic data 
into clinical practice is that cellular response to gross genetic abnormalities remains largely 
unknown. Here we use metabolomics to demonstrate that regardless of translocation 
partner, patient-derived BCP-ALL cells harboring IGH locus anomalies demonstrate 
similar dysregulations in metabolism indicating potential targets for novel therapeutics.  
 
3.3 MATERIALS AND METHODS 
3.3.1 Reagents and chemicals 
Tissue culture reagents were purchased from GE Healthcare Biosciences (Pittsburg, 
PA, USA) unless specified otherwise. Mass spectrometry grade water, methanol, 
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acetonitrile, 2-propanol, chloroform, ammonium formate, and formic acid, as well as 
molecular biology grade ethanol, dimethyl sulfoxide (DMSO), and 2,6-di-tert-butyl-4-
methylphenol (BHT) were purchased from Thermo Fisher Scientific (Waltham, MA, 
USA). Hanks’ Balanced Salt Solution (HBSS), Ficoll-Paque Plus, and commercial 
calibration solutions for the mass spectrometer were also purchased from Thermo Fisher 
Scientific. A library containing 291 unique anti-cancer compounds was purchased for high-
throughput screening (Table A3; Cambridge Cancer Compound Library (CCL); Selleck 
Chemicals, LLC, Houston, TX, USA). The following isotopically labeled compounds were 
purchased from Cambridge Isotope Laboratories (Tewksbury, MA, USA): 13C1-glucose, 
D4-alanine, D3-serine, D2-glycine, D4-citric acid, D3-malic acid, D4-succinic acid, D2-
fumaric acid, D3-aspartic acid, D4-L-lysine, D4-cystine, D3-DL-glutamic acid, D5-
glutamine, and D5-L-tryptophan. For non-polar analyses, SPLASH LipidoMix mass 
spectrometry standard was purchased from Avanti Polar Lipids (Alabaster, AL, USA).   
3.3.2 Declaration of ethical approval 
Clinical investigations were conducted in accordance with the Declaration of 
Helsinki principles. Human studies were approved by both the UT Austin Health Science 
(2013-06-0047, 2018-05-0129) and Ascension Seton (CR-13-161) Institutional Review 
Boards (IRB). Written informed consent and parental/guardian permission were obtained 
prior to specimen collection and study inclusion.  
3.3.3 Patients and clinical outcomes 
Patients were recruited by the clinical staff at the Children’s Blood and Cancer 
Center at the Dell Pediatric Medical Center in Austin, Texas. Bone marrow (BM) aspirates 
were collected at diagnosis and throughout treatment following written and informed 
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consent and parental/guardian permission. Specimen collection was performed in 
accordance with IRB guidelines. To be eligible for the study, patients were required to be 
between one to 21 years of age at the time of leukemia diagnosis (new or relapse). Clinical 
measures including age, gender, weight, body mass index (BMI), race, ethnicity, risk 
classification, minimal residual disease (MRD), histopathology (flow cytometry, 
karyotype, and fluorescence in situ hybridization (FISH), where applicable) were reported 
following diagnosis. Nonparametric Wilcoxon rank sum tests were performed on patient 
age, weight, and BMI [211, 212]. All patients were treated following Children’s Oncology 
Group (COG) protocols as determined by diagnosis and risk assessment (Table 3.1). 
Patients diagnosed with precursor B-cell acute lymphoblastic leukemia (BCP-ALL) were 
treated in accordance with COG protocol AALL0932 (standard risk), AALL1131 (high 
risk), or AALL1122 (Philadelphia chromosome positive). Treatment roadmaps can be 
found in Appendix C. Clinical risk assessment at diagnosis included age, sex, white blood 
cell count, and presence of leukemia cells in cerebrospinal fluid. A small number of 
cytogenetic markers are also used (once available). Last, response to therapy, as measured 
by minimal residual disease during or following induction is used to establish patient risk. 
 
Table 3.1: Established parameters for clinical risk assessment of pediatric BCP-ALL 
patients 
Very few modern markers for patient risk stratification are currently being used clinically. 
WBC, white blood cells; CNS, central nervous system; MRD, minimal residual disease; 
ND, not detected; D, detected, Ph+, Philadelphia chromosome positive; Ph-like, 
Philadelphia like; MLL, mixed lineage leukemia translocation.  
 
Parameter Standard Risk High Risk 
Age (years) <10 ≥10 
Sex Female Male 
WBC count (per µL) <50,000 >50,000 
CNS infiltration ND D 
MRD (Induction) Negative Positive 
Cytogenetics Hyperdiploid Hypodiploid, Ph+, Ph-like, MLL 
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3.3.4 Sample preparation 
Patient specimens were collected in heparinized vacuum blood collection tubes 
(Becton, Dickenson and Company, Franklin Lakes, New Jersey, USA). Blood plasma and 
bone marrow supernatant were isolated by centrifugation at 400 g for 20 minutes at 18°C. 
A 1 mL aliquot of plasma or supernatant was immediately snap frozen in liquid nitrogen 
and stored at -80°C prior to analysis. Leukemia cells were isolated using a modified Ficoll-
Paque protocol. Briefly, the remaining blood was diluted 1:1 with ice cold Hanks’ Balanced 
Salt Solution (HBSS) and layered over 3 mL of Ficoll-Paque Plus solution. Specimens 
were then centrifuged at 400 g without brake for 30 minutes at 18°C. The mononuclear cell 
layer was collected and washed twice with ice cold 10 mL of HBSS. Cells were counted, 
pelleted, snap frozen in liquid nitrogen, and stored at -80°C prior to analysis.  
For analysis of the extracellular environment, aliquots of biofluid supernatant were 
ultrafiltered (Nanosep 3K Omega centrifugal devices; Pall Corporation, Port Washington, 
NY, USA) to remove protein and lipid components as previously reported [68, 93]. In brief, 
centrifugal filters were washed twice within 24 hours with MilliQ water (Millipore). 
Biofluids were thawed on ice, vortexed, and a 600 µL aliquot was transferred to the filter. 
Samples were centrifuged at 14,600 g and 4°C for up to 24 hours. The polar filtrate was 
transferred on ice to LC-MS vials and spiked with 14 stable isotope-labeled polar internal 
standards (IS) at a final concentration of 0.2 ppm. For intracellular analysis, metabolites 
were extracted from cell pellets by modified Bligh-Dyer, similar to previously reported 
[138]. In brief, cell pellets were extracted with ice cold 1:1 water:methanol and equal parts 
chloroform. BHT was added to preserve metabolites susceptible to oxidation. Polar and 
non-polar fractions were isolated and evaporated to dryness at 4°C in a CentriVap 
refrigerated vacuum concentrator (Labconco, Kansas City, MO, USA). Polar fractions 
were resuspended in water containing 14 IS at 0.2 ppm and transferred to LC-MS vials for 
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immediate analysis. Aliquots of non-polar metabolites were spiked with 10 µL of SPLASH 
LipidoMix (supplied in methanol), resuspended in 100 mM ammonium formate in 65:35 
acetonitrile:2-propanol, and were transferred into 96-well microplates (Eppendorf, 
Hamburg, Germany). Filled microplates were heat sealed with pierceable foil sheets (ALPS 
50V Manual Heat Sealer; Thermo Fisher Scientific, Waltham, MA, USA) and kept at -
80°C until analysis.  
3.3.5 Ultrahigh performance liquid chromatography-mass spectrometry (UPLC-
MS) analysis 
Chromatographic separation was achieved on a Vanquish Flex UPLC system 
equipped with a quaternary pump, vacuum degasser, column compartment, and split 
autosampler with temperature controller (5°C; Fisher Scientific, Bremen, Germany). A 
Kinetex 2.6 µm C18 100 Å, 150 x 2.1 mm HPLC column (Phenomenex, Torrance, CA, 
USA) was used for untargeted polar metabolite analysis. Mobile phase A was water with 
0.2% formic acid and mobile phase B was methanol. A gradient separation was performed 
holding 2% B for 4 minutes, then a linear increase to 80% B over 10 minutes, followed by 
another linear increase to 98% B over 1 minute, then washing with 98% B for 6 minutes, 
and column equilibration with 2% B for 14 minutes. The total run time was 35 minutes 
with a flow rate of 150 µL/min and an injection volume of 5 µL. Eluent was coupled to a 
Q Exactive Hybrid Quadrupole Orbitrap mass spectrometer with an electrospray ionization 
(ESI) source simultaneously operating in fast negative/positive ion switching mode 
(Thermo Scientific, Bremen, Germany). The following acquisition settings were used for 
data collection in full MS mode: spray voltage, 4 kV (pve), 3.5 kV (nve); capillary 
temperature, 320°C; sheath gas, 45 (arbitrary units); auxiliary gas, 10 (arbitrary units); m/z 
range, 50-750; data acquisition, centroid mode; microscans, 10; AGC target, 1e6; 
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maximum injection time, 200 ms; mass resolution, 70,000 FWHM at m/z 200. Accuracy 
of the instrument was ensured by calibrating the detector prior to analysis. Mass tolerance 
was maintained at 5 ppm in all cases. Internal standards were used to monitor retention 
time, ionization efficiency, and instrument stability during analysis. 
The ultrahigh performance liquid chromatography-mass spectrometry (UPLC-MS) 
analytical platform was controlled by an external computer operating the Xcalibur software 
package (version 2.2 SP1.48; Thermo Scientific, San Jose, CA, USA). Raw files were 
processed using SIEVE 2.2.0 SP2 (Thermo Scientific, San Jose, CA, USA) and an in-house 
script that operates in the MATLAB programming environment. Spectral alignment and 
peak picking were performed in SIEVE. Integrated intensities, monoisotopic masses, and 
retention times were exported for further analysis in the MATLAB programming 
environment. Metabolite identifications were determined by matching accurate masses and 
retention times to a mass spectral metabolite library of standards (IROA 300, Mass 
Spectrometry Metabolite Library of Standards (MSMLS); IROA Technologies, Sea Girt, 
NJ, USA). A pooled quality control (QC) was used to monitor instrument stability and a 
blank was used for background subtraction. Peaks were only included in further analyses 
if the coefficient of variance (CV) was <0.25 and >0 in the QC replicates. Probabilistic 
quotient normalization (PQN) was performed prior to statistical analyses [162]. Pathway 
analysis was performed with MetaboAnalyst on confirmed features [163, 213, 214]. 
3.3.6 Direct infusion mass spectrometry (DIMS) analysis 
Sample plates were thawed on ice and centrifuged at 2500 g for 10 minutes at 4°C. 
Acquisition was performed on a Q Exactive Hybrid Quadrupole Orbitrap mass 
spectrometer equipped with an automated chip-based nanoelectrospray ionization (nESI) 
source (TriVersa NanoMate; Advion, Ithaca, NY, USA). The direct infusion nESI was 
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controlled by ChipSoft software (version 8.3.3; Advion) with the following acquisition 
conditions: gas pressure, 0.4 psi; spray voltage, 1.3 kV; injection volume, 5 µL; acquisition 
time, 30 s (per mode). Simultaneously, the mass spectrometer acquisition conditions were 
capillary temperature, 250°C; m/z range, 150-2000; data acquisition, centroid mode; 
microscans, 1; AGC target, 3e6; mass resolution, 70,000 FWHM at m/z 200. The mass 
spectrometer was controlled with the Xcalibur software package (version 2.2 SP1.48). 
Calibration of the mass spectrometer was achieved as described above. Tandem mass 
spectrometry (MS2) data was acquired on a pooled QC sample for metabolite annotation. 
Sample microplates were maintained at 4°C for the duration of analysis.  
Raw files were converted into mzXML files by MSConvert [215] and processed by 
in-house MATLAB scripts. Following normalization, peaks were included in analysis if 
the coefficient of variance (CV) was <0.25 and >0 in the QC replicates. Tandem MS2 data 
facilitated the differentiation of complex lipid polar head groups. Positively annotated 
lipids are reported with MS2 confirmed classifications and accurate ion masses. 
3.3.7 In vitro screening 
Cell lines were expanded, tested for mycoplasma, and stored cryogenically before 
screening. Suspension cells were cultured in RPMI-1640 medium supplemented with 10% 
characterized fetal bovine serum (FBS) and 2 mM L-glutamine. Adherent cells were 
cultured in DMEM high glucose supplemented with 10% characterized or MSC-qualified 
FBS and 2 mM L-glutamine. Stromal cells, HS-5 and HS-27A, were purchased from the 
American Type Culture Collection (ATCC; Manassas, VA, USA). Mesenchymal stem 
cells (MSC) were a gift from the laboratory of Dr. Laura Suggs (The University of Texas 
at Austin, Austin, TX, USA). Suspension cells, BALL-1 and Tanoue, were a generous gift 
from Dr. Marina Konopleva (The University of Texas MD Anderson Cancer Center, 
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Houston, TX, USA). Cells were incubated under standard conditions at 37°C and 5% CO2. 
Suspension cells were maintained at a concentration range of 200,000 to 2 x 106 cells/mL 
and adherent cells were split via trypsinization at 70 – 90% confluency. 
For screening, an automated pipetting system was used to ensure the consistency 
of seeding (VIAFLO 384; INTEGRA Biosciences, Hudson, NH, USA). Cells were seeded 
into 384-well white polystyrene microplates, as previously reported [216]. Here, cells were 
treated with the Cambridge Cancer Compound Library (CCL) at a final concentration of 
100 nM and incubated for 24 hours. For each cell line, at least four replicates were plated. 
Following incubation, cell viability was assessed by adenosine triphosphate (ATP) 
luminescence (Cell Titer Glo (CTG); Promega, Madison, WI, USA). The manufacturer’s 
protocol was followed for the CTG assay. Briefly, in a dark room, plates were equilibrated 
to room temperature for 30 minutes prior to the addition of the CTG reagent. Reagent was 
dispensed using the automatic pipetting system described above. Plates were placed on a 
platform mixer (MixMate; Eppendorf, Hamburg, Germany) for two minutes at 700 rpm to 
homogenize lysate. Following mixing, plates were equilibrated for an additional 10 
minutes to allow the luminescence signal to stabilize. Endpoint luminescence with a 1000 
ms integration time was recorded as a surrogate for cell viability. A Dixon’s Q test was 
applied to all raw data points prior to normalization to identify outliers that could lead to 
potential false positive or false negative results [156]. Luminescence intensities were 
normalized to the vehicle control for each plate. Averages, standard deviations, and z-
scores were calculated for each compound and cell line combination. Statistical 




3.4.1 Clinical and demographic characteristics of BCP-ALL patients 
 Fresh BM was collected from 41 patients with BCP-ALL at the time of diagnosis. 
Patient characteristics and demographics are reported in Table 3.2. The median age was 7 
(interquartile range (IQR) = 4–12). There were more females than males (18 males, 23 
females). Most patients identified as white (83%) and Hispanic (59%). Patients were nearly 
evenly split between high/very high and low/standard risk groups (22 and 19, respectively). 
Low and standard risk patients were treated by COG protocol AALL0932 (Form C1). 
Patients classified as high or very high risk were treated according to COG protocol 
AALL1131 (Form C2), with the exception of BCR-ABL1 and BCR-ABL1-like, which were 
treated according to COG protocol AALL1122 (Form C3). With the exception of those on 
AALL1122, all patients were treated with a combination of cytarabine, vincristine, 
methotrexate, L-asparaginase, and a glucocorticoid (either dexamethasone or prednisone). 
Patients on AALL1131 also received daunorubicin. 
 There were minimal differences between patients with an identified anomaly at the 
IGH locus and those without IGH aberrations. Wilcoxon rank sum tests on age, weight, 
and BMI yielded p-values of 0.1395, 0.0578, and 0.1409, respectively. For clinical data, a 
threshold for statistical significance is often set at p-value ≤0.1, as opposed to the standard 
α ≤0.05, due to higher variability between patients than genetically identical mice or in 
vitro models. If the significance threshold is set at ≤0.1, patient weight is statistically 
significant between groups. However, this is likely due to two factors. First, although not 
statistically significant, IGH mutant patient ages trended higher and older children and 
adolescents tend to weight more as they grow. Second, two patients in the IGH mutant 
group were classified as obese with BMI >40 and weight >100 kg placing them both at or 
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above the 99th percentile for their respective sex and age. Sex, race, and ethnicity 
classifications were also similar between groups. The non-IGH group was 58% female, 
whereas the IGH group was evenly split between males and females. The non-IGH group 
also contained more patients identifying as white (87%)  than the IGH group (70%). 
Ethnicity was very similar at 58% and 60% Hispanic for non-IGH and IGH groups, 
respectively. Importantly, aberrations at the IGH locus were associated with the high and 
very high risk disease classification (80%). Risk was more evenly distributed in the non-
IGH group (45% low or standard risk and 55% high or very high risk).  
 
Table 3.2: Pediatric BCP-ALL patient characteristics and demographics indicated 
that IGH locus aberrations are associated with higher risk  
Patient characteristics and demographics were similar between groups. Median values with 
interquartile ranges (IQR) are reported for age, weight, and BMI. Sex, race, and ethnicity 
distributions were similar. BCP-ALL, precursor B-cell acute lymphoblastic leukemia; 
IGH, immunoglobulin heavy chain; BMI, body mass index.  
 
Characteristic Total Non-IGH IGH Mutant 
Age (years) 7 (4–12) 6 (4–10) 11 (6–13) 





Weight (kg) 25.8 (19.1–47.1) 25.4 (18.4–37.8) 38.6 (24.0–68.1) 


























22 High/Very High 
19 Low/Standard 
14 High/Very High 
17 Low/Standard 
8 High/Very High 
2 Low/Standard 
 62 
3.4.2 Polar metabolomics analysis by UPLC-MS 
 Untargeted metabolomics analysis was performed on intracellular extracts from 
bone marrow-derived cells collected from patients at the time of diagnosis. Features 
extracted from UPLC-MS acquisition were matched to a mass spectral metabolite library 
of standards containing accurate masses and chromatographic retention times. This 
resulted in the positive identification of 128 metabolites present in most samples. Twenty-
four positively identified metabolites were statistically significant between patients with 
an aberration at the IGH locus and patients without an IGH mutation (p-value ≤0.1). 
Statistically significant metabolites included several canonical amino acids (glutamate, 
glutamine, threonine, tryptophan, glycine, and aspartate) and non-canonical amino acids 
and amino acid-related compounds (taurine, hypotaurine, homocysteine, N-
acetylglucosamine, and trimethyllysine). Fold change differences between the IGH and 
non-IGH groups were calculated relative to the non-IGH group (Figure 3.1). The non-
canonical amino acids, taurine, hypotaurine, and homocysteine were all increased in the 
IGH mutant group. Conversely, trimethyllysine and N-acetylglucosamine were decreased 
in IGH patient cells (p = 0.0145 and 0.0102, respectively). Glutathione (GSH) was also 
significantly increased in the IGH mutant group (p = 0.0583). While oxidized glutathione 
(GSSG) was not statistically significant, the ratio [GSH]/[GSSG] was > 2.5 times larger in 
the IGH mutant group. The glutathione ratio was 422 in the IGH group as compared to 160 
in the non-IGH group (data not shown).  
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Figure 3.1: Amino acids and related metabolites were significantly elevated in 
pediatric BCP-ALL patients with an IGH locus aberration 
Relative metabolite levels as measured by UPLC-MS. Fold change calculated relative to 
patients without IGH locus anomalies. Color bar indicates p-value. UPLC-MS, ultrahigh 
performance liquid chromatography-mass spectrometry; BCP-ALL, precursor B-cell acute 
lymphoblastic leukemia; IGH, immunoglobulin heavy chain. 
 
 In addition to amino acid and amino acid-related compounds, several nucleotides, 
energy metabolism intermediates, and polar metabolites involved in lipid metabolism 
were identified (Figure 3.2). Contrary to most amino acids, trends in nucleotides 
indicated decreases in the IGH mutant group relative to the non-IGH group. While only 
cyclic CMP (cytosine monophosphate) and GMP (guanosine monophosphate) were 
statistically significant (p = 0.0201 and 0.0664, respectively), most identified nucleotides 
demonstrated similar patterns. On the other hand, glucose was significantly increased in 
the IGH mutant group (p = 0.0739) but the remaining glycolytic intermediates were 
decreased (although not statistically significant). Similar to glucose, polar metabolites 
involved in lipid metabolism (ethanolamine phosphate, methyl propionate, sphinganine, 
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and suberic acid) were significantly increased in the IGH mutant group suggesting lipid 




Figure 3.2: UPLC-MS analysis indicated distinct trends in nucleotide, energy, and 
lipid metabolism in pediatric BCP-ALL patients with an IGH locus aberration 
Fold change calculated relative to patients without IGH locus anomalies. Color bar 
indicates p-value. UPLC-MS, ultrahigh performance liquid chromatography-mass 
spectrometry; BCP-ALL, precursor B-cell acute lymphoblastic leukemia; IGH, 
immunoglobulin heavy chain; AMP, adenosine monophosphate;  ADP, adenosine 
diphosphate; CDP, cytidine diphosphate; GMP, guanosine monophosphate; IMP, inosine 
monophosphate; UMP, uridine monophosphate; UDP, uridine diphosphate; XMP, 
xanthosine monophosphate.  
3.4.3 Pathway analysis of metabolite profiles 
To contextualize the results of UPLC-MS analysis, pathway analysis was 
performed using the online software MetaboAnalyst [163]. Pathways implicated are 
reported in Table 3.3. Pathways were considered consequential if they had a p-value <0.1 
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and/or an impact >0.2. These parameters yielded 12 pathways of interest. Overall, these 
pathways fell under three main categories: amino acid, nucleotide, and energy metabolism. 
The key amino acid pathways were glutamate metabolism (p = 0.0080), aspartate 
metabolism (p = 0.0157), and glutathione metabolism (p = 0.0348). In addition to being 
important for protein synthesis and energy metabolism, aspartate and glutamate are also 
central to nucleotide synthesis. The impact of glutathione metabolism may be related to 
amino acid metabolism as glutathione is a tripeptide or may play a role in ameliorating 
reactive oxygen species (ROS). With regard to nucleotide synthesis, purine metabolism 
and pyrimidine metabolism were both statistically significant (p = 0.0082 and 0.0628, 
respectively). Additionally, the pentose phosphate pathway  and the Warburg effect were 
statistically significant (p = 0.0715 and 0.0717, respectively) providing additional support 
that glycolytic flux was dysregulated. Several pathways involved in phospholipid 
metabolism were identified as statistically significant, but their impact was unclear because 
the number of hits was low (<5). However, this is not unexpected given that only polar 
metabolites were included in the pathway analysis. These findings did prompt further 
investigation into the role of lipid metabolism in patients with IGH locus anomalies.  
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Table 3.3: Pathway analysis indicated significant differences in amino acid, 
nucleotide, and energy metabolism 
Pathway analysis was performed on UPLC-MS features positively annotated by accurate 
mass and retention time. Hits indicates the number of identified compounds over the total 
number of compounds in the specified pathway, according to SMPDB. Pathways were 
included if the p-value <0.1 and/or the impact was >0.2. UPLC-MS, ultrahigh performance 
liquid chromatography-mass spectrometry; SMPDB, small molecule pathway database; 
TCA, tricarboxylic acid cycle. 
 
Pathway Hits Impact p-value 
Glutamate metabolism 10/45 0.0742 0.0080 
Purine metabolism 13/63 0.1853 0.0082 
Aspartate metabolism 8/34 0.8000 0.0157 
Glutathione metabolism 5/19 0.4724 0.0348 
Pyrimidine metabolism 9/54 0.4306 0.0628 
Pentose phosphate pathway 6/57 0.3118 0.0715 
Warburg effect 10/49 0.2037 0.0717 
Urea cycle 6/23 0.3908 0.1064 
TCA cycle 6/26 0.2299 0.1067 
Amino sugar metabolism 6/31 0.2204 0.1310 
Arginine & proline metabolism 9/48 0.2822 0.1985 
Cysteine metabolism 5/24 0.4200 0.2664 
3.4.4 Complex lipid analysis by DIMS 
Approximately 500 complex lipid species were annotated by direct infusion mass 
spectrometry (DIMS). A broad range of lipid classes were identified including: 
monoglycerides (MG), diglycerides (DG), triglycerides (TG), phosphatidic acids (PA), 
phosphatidylcholines (PC), phosphatidylethanolamines (PE), phosphatidylglycerol (PG), 
phosphatidylinositols (PI), phosphatidylserines (PS), cholesterol esters (CE), and 
sphingomyelins (SM). Complex lipids are particularly difficult to assign a single molecular 
identification because any given species has a number of isomers that share the same 
accurate mass. The similarity in structures between classes and fragmentation patterns of 
the glycerol backbone, polar heads, and fatty acid chains of varying lengths and degrees of 
saturation further complicate the mass spectra of mixed samples. In order to simplify the 
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analysis, annotated lipids were identified by two key features: lipid classification and ion 
mass (m/z). MS2 analysis differentiated lipid classifications. However, a small number of 
PC and PE species were indistinguishable and are thus reported as PC/PE for transparency. 
Of the nearly 500 lipids positively annotated by DIMS, 40 were statistically significant (p-
value ≤0.1) between patients harboring IGH locus anomalies and those that did not have 
an IGH mutation (Figure 3.3). Fold changes were calculated between the IGH mutant and 
non-IGH group, relative to the non-IGH patient group. Small, but strongly significant 
decreases in most MG, DG, and TG were associated with anomalies at the IGH locus. 
Moreover, larger and significant increases in PC, PE, PS, and SM species were associated 
with IGH locus aberrations. Of note, for MG, PS, and SM, only one or two species were 
statistically significant, thus the global contributions of these classes remain unclear. 
Overall, these data indicate that patients with IGH locus mutations have unique lipid 
profiles that are characterized by diminished quantities of DG and TG species and 
significantly increased abundances of PC and PE species. 
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Figure 3.3: Fold change differences in lipid concentrations between BCP-ALL 
patients with chromosomal anomalies at the IGH locus and non-IGH mutants  
Color bar indicates p-value calculated by independent Student’s t-test. Fold change was 
calculated relative to the non-IGH mutant group. Numeric value indicates the m/z of the 
lipid species identified. BCP-ALL, precursor B-cell acute lymphoblastic leukemia; IGH, 
immunoglobulin heavy chain; MG, monoglyceride; DG, diglyceride; TG, triglyceride; PA, 
phosphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PS, 
phosphatidylserine; SM, sphingomyelin.  
3.4.5 Cambridge cancer compound library (CCL) screening 
 A customized version of the Cambridge cancer compound library (CCL) composed 
of 291 unique compounds was assessed for cytotoxicity as measured by ATP luminescence 
in two BCP-ALL cell lines carrying cytogenetic anomalies at the IGH locus. BALL-1 was 
established from the peripheral blood of a 75 year-old-man with BCP-ALL and carries a 
biallelic rearrangement of IGH with CCND1 (Cyclin D1; t(11;14)(q13;q32)) and MYC 
(t(8;14)(q24;q32)) [217, 218]. Tanoue was established from the peripheral blood of an 11 
year-old-boy with BCP-ALL and carries a single copy of the IGH-MYC translocation 
t(8;14)(q24;q32) [219]. Cells were treated with a final concentration of 100 nM and 
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efficacy was assessed 24 hours after treatment. There were 62 compounds that resulted in 
an average relative viability of ≤90% in BALL-1 and Tanoue cells (Figure 3.4). Of those, 
13 compounds yielded an average relative viability of ≤70% in both cell lines (Table 3.4). 
Importantly, the most effective compounds appear to target heat shock protein (HSP; 2), 
proteasome (2), mammalian target of rapamycin (mTOR; 4), and histone deacetylase 
(HDAC; 3) activities. The two remaining compounds were an inhibitor of survivin 
(YM155, sepantronium bromide) and the anti-folate anti-metabolite, methotrexate, 
currently used for induction therapy in both AALL0932 and AALL1131. Three of these 
compounds have been FDA approved: bortezomib, panobinostat, and methotrexate. 
Bortezomib is approved by the FDA for treatment of multiple myeloma and mantle cell 
lymphoma. Similarly, panobinostat is FDA approved for use in patients with multiple 
myeloma. Finally, methotrexate is FDA approved for treatment of many cancers including 
leukemia and lymphoma. Nine of the remaining 10 compounds are in Phase 1 or 2 clinical 
trials in one or more malignancies, indicating their promise as novel therapeutics. Only 
Torin 2 is not currently being investigated in clinical trial.  
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Figure 3.4: Screening of CCL indicated similar cell viability patterns in BCP-ALL 
cell lines carrying IGH locus anomalies 
Viability measured by ATP luminescence 24 hours after treatment will 100 nM CCL. A 
total of 291 compounds were evaluated. Shown are the 62 compounds that inhibited 
viability in both BALL-1 and Tanoue by ≥10% relative to vehicle control. CCL, Cambridge 
cancer compound library; BCP-ALL, precursor B-cell acute lymphoblastic leukemia; IGH, 
immunoglobulin heavy chain.  
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Table 3.4: CCL candidates that decreased viability in cell lines carrying IGH locus 
aberrations were inhibitors of heat shock protein, proteasome, mTOR, and HDAC 
activities 
Mean viability of four replicates reported relative to vehicle control. HSP, heat shock 
protein; mTOR, mammalian target of rapamycin; DHFR, dihydrofolate reductase; HDAC, 
histone deacetylases. 
 
Compound Alias Target BALL-1 Tanoue 
AUY922 (NVP-AUY922) Luminespib HSP 0.65 0.58 
AZD8055  mTOR 0.70 0.67 
Bortezomib (PS-341) Velcade Proteasome 0.04 0.61 
Disulfiram  Antabuse Proteasome 0.40 0.44 
Elesclomol (STA-4783)  HSP 0.35 0.35 
GSK2126458 (GSK458) Omipalisib mTOR 0.66 0.59 
INK 128 (MLN0128) Sapanisertib mTOR 0.66 0.62 
Methotrexate  DHFR 0.59 0.56 
Panobinostat (LBH589) Farydak HDAC 0.37 0.59 
PCI-24781 (Abexinostat)  HDAC 0.46 0.66 
Torin 2  mTOR 0.58 0.60 
Trichostatin A (TSA)  HDAC 0.37 0.59 
YM155 (Sepantronium Bromide)  Survivin 0.09 0.35 
 
3.5 DISCUSSION 
Pediatric patients with hematological malignancies were recruited at the time of 
diagnosis. For this analysis, patients were grouped based on their primary cytogenetic 
anomalies. Preliminary evidence suggested distinct metabolic profiles of leukemia cells 
derived from patients with aberrations at the IGH locus. Overall, patient characteristics and 
demographics were similar between groups. There were minimal differences in age, 
weight, and BMI. Using the standard clinical cutoff for statistical significance (p-value 
≤0.1) only weight was statistically significant between the IGH mutant group and the non-
IGH group. This is most likely explained by the fact that two of the patients in the IGH 
group were obese and ranked at or above the 99th percentile for their age and sex. Similarly, 
sex, race, and ethnicity were similar between groups. Thus, differences in the metabolic 
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profiles do not appear to be attributable to these clinical features. The one important 
distinction between the groups was that patients harboring an IGH locus aberration were 
more likely to be classified as high or very high risk whereas the distribution was more 
even in the non-IGH group. This finding is consistent with previous studies indicating 
poorer outcomes for patients with IGH locus anomalies [44, 185, 201, 209, 210].  
Metabolomics and pathway analyses of the polar and non-polar fractions of bone 
marrow-derived BCP-ALL cells collected from patients at the time of diagnosis indicated 
distinct profiles in patients with anomalies at the IGH locus. Metabolomics analysis 
indicated significant increases in the IGH group of several amino acids, amino acid-related 
compounds, and glucose. Significant increases were also observed in PC and PE lipid 
species and polar metabolites important in lipid metabolism. Nucleotides were generally 
decreased in in the IGH group as were intermediates in central energy metabolism 
(glycolysis and TCA cycle). Pathway analysis confirmed the central importance of amino 
acid, nucleotide, and energy metabolism. Combined these results indicate that aberrations 
at the IGH locus result in a unique metabolic profile. IGH locus anomalies often result in 
overexpression of partner genes due to the proximity of the IGH enhancer region. While 
recurrent translocations into the IGH locus are not directly involved in metabolism, many 
have important roles in cell cycle, apoptosis and survival, proliferation, and differentiation. 
Cytokine receptor-like factor 2 (CRLF2), erythropoietin receptor (EPOR), and interleukin 
3 (IL3) activate the JAK-STAT signaling pathway which has been shown to directly 
regulate lipid metabolism in adipocytes [220, 221]. This activity has not been observed in 
BCL-ALL and our findings may be the result of either dysregulated lipid metabolism in 
leukemia cells and/or crosstalk between leukemia cells and adipocytes in the bone marrow 
tumor microenvironment. The translocation partner, B-cell lymphoma 2 (BCL2), primarily 
know for inhibiting apoptosis also controls metabolic activity and insulin under cellular 
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stress [222].  Another member of the BCL2 family, BCL-XL, has been shown to alter 
mitochondrial physiology to promote survival under stress [223]. Further studies will be 
needed to determine whether either of these activities contribute to dysregulated 
metabolism in BCP-ALL cells. Lastly, MYC translocations at the IGH locus account for 
the majority of Burkitt’s lymphoma cases and many BCP-ALL cases harboring an IGH 
translocation. MYC is a proto-oncogene involved in cell cycle progression, apoptosis, and 
cellular transformation. MYC has also been shown regulate the expression of enzyme 
involved in glycolysis, nucleotide synthesis, and lipid synthesis  [60, 224]. Furthermore, 
MYC appears to work in concert with mTOR to exacerbate metabolic dysregulation in 
cancer cells. While MYC upregulates glycolysis and biosynthesis of lipids and nucleotides, 
mTOR increases uptake of glucose and amino acids and upregulates protein synthesis [60].   
The concerted upregulation of biosynthetic pathways and energy production for 
rapid proliferation by MYC and mTOR may explain the efficacy of mTOR inhibitors on 
IGH mutant cells screened with the customized library. Of 291 total compounds, 13 
compounds yielded an average viability of ≤70% of control, in both cell lines. Four of the 
top candidates were mTOR inhibitors, indicating that the increased uptake of small 
molecules to support proliferation is essential for survival of IGH mutants. Related, two 
proteasome inhibitors were also top candidates, confirming a dependence on free amino 
acids for protein synthesis. There were also three histone deacetylase inhibitors in the top 
candidates. HDAC inhibitors target multiple processes important in IGH mutant BCP-ALL 
including intrinsic apoptosis, cell cycle arrest, and regulation of ROS [225]. Moreover, 
HDAC inhibitors disrupt the protein chaperone function of heat shock proteins (HSP) 
[226]. Two HSP inhibitors were also top candidates for inhibiting leukemia cell viability. 
In addition to functioning as chaperones for new and misfolded proteins, there is evidence 
that ROS regulate HSP activity [227]. Taken together, the top library candidates identified 
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by high-throughput screening support the central role of amino acid, nucleotide, energy, 
and lipid metabolism to support the survival of BCP-ALL cells harboring an aberration at 
the IGH locus. More importantly, several novel therapeutic targets were identified that 
could decrease the toxic burden and improve both short- and long- term outcomes for 
patients with an IGH locus anomalies. 
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Chapter 4: Concluding Remarks 
4.1 CONCLUSIONS 
 The aim of this research was to elucidate targetable metabolic vulnerabilities in 
BCP-ALL to improve outcomes in pediatric patients. This was achieved by combining 
high-throughput screening, ultrahigh performance liquid chromatography-mass 
spectrometry, direct infusion mass spectrometry, metabolic flux analysis, and pathway 
analysis. These tools were combined to investigate two main avenues of research. First, a 
non-toxic therapeutic strategy was explored by identifying a synergistic combination of 
natural products by high-throughput screening followed by untargeted metabolomics and 
metabolic flux analysis to provide mechanistic insights. Second, untargeted metabolomics 
analyses were performed on bone marrow-derived BCP-ALL patient cells to support the 
clinical use of metabolic markers for risk stratification. This was followed up with high-
throughput screening of a customized chemotherapeutic compound library to identify 
novel drug targets. Together these avenues of research address the central challenge in 
pediatric leukemia – administering a robust treatment to induce remission while causing 
minimal physiological and psychological harm to young patients.  
 The first study identified a synergistic combination of DMAPT and SHK. This 
combination resulted in the net reduction of many nucleotides, amino acids, and TCA cycle 
intermediates. Pathway analysis confirmed the central role of amino acid and nucleotide 
metabolism in BCP-ALL. Metabolic flux analysis demonstrated that the combination of 
DMAPT and SHK resulted in decreased shunting of metabolites from glycolysis into the 
pentose phosphate pathway for nucleotide synthesis. Glutaminolysis was also reduced 
leading to a decrease in both oxidative and reductive TCA cycle flux as well as downstream 
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pathways. In combination, DMAPT and SHK induced measurable changes in intracellular 
metabolism that promoted pro-apoptotic signaling and resulted in leukemia cell death.  
 The second study aimed to correlate metabolic profiles with recurrent cytogenetic 
anomalies in pediatric BCP-ALL patients. Intracellular metabolic profiles of patients with 
IGH locus anomalies were distinct from patients without an aberration at this locus. 
Interrogation of identified metabolites indicated significant increases in amino acids, 
amino acid-related compounds, and glucose in IGH mutants. Polar metabolites involved in 
lipid metabolism were also significantly increased. Analysis of nonpolar metabolites 
indicated small, but significant decreases in DG and TG in addition to larger significant 
increases in PC and PE. Pathway analysis corroborated the vital role of amino acid and 
nucleotide metabolism. High-throughput screening of a customized chemotherapeutic 
compound library identified several promising novel therapeutics for patients harboring 
IGH locus anomalies that target HSP, proteasome, mTOR, and HDAC activities. 
Collectively, these findings indicate the clinical relevance and application of metabolomics 
for improving patient stratification.  
4.2 FUTURE DIRECTIONS 
The ongoing collaboration with the Children’s Blood and Cancer Center has 
resulted in a large number of peripheral blood (PB) and bone marrow (BM) aspirates 
collected at diagnosis and throughout treatment. Future studies will evaluate the 
intracellular profiles of leukemia cells in circulation, the extracellular environment in BM 
and PB, and patient stratification based on other relevant and recurring cytogenetic 
anomalies. Finally, intracellular and extracellular PB specimens have been collected from 
a cohort of heathy children to interrogate the differences in metabolic profiles in leukemia 
patients at diagnosis and following induction as compared to their healthy counterparts.  
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Appendix A: Supplementary Tables 
Table A1: Comprehensive list of compounds included in the natural products library  
Screening library was purchased from Selleck Chemicals, formatted in to 384-well plates, 




(+)-Usniacin (D-Usnic acid) 7562-61-0
10-Hydroxycamptothecin 19685-09-7





















Biochanin A (4-Methylgenistein) 491-80-5
Butylscopolamine bromide (Scopolamine butylbromide) 149-64-4
Caffeic acid 331-39-5
Caffeic acid phenylethyl ester 104594-70-9
Chlorogenic acid 327-97-9
Chrysin 480-40-0





Cyclosporin A (Cyclosporine A) 59865-13-3, 55126-45-9, 56645-58-0
Cytisine (Baphitoxine, Sophorine) 485-35-8
Dihydroartemisinin (DHA) 71939-50-9
Dihydromyricetin (Ampeloptin) 27200-12-0
Dioscin (Collettiside III) 19057-60-4











































Morin hydrate (Aurantica) 6202-27-3
Myricetin (Cannabiscetin) 529-44-2
Myricitrin (Myricitrine) 17912-87-7
Nalidixic acid (NegGram) 389-08-2
Naringenin 480-41-1
Naringin (Naringoside) 10236-47-2
Naringin Dihydrochalcone (Naringin DC) 18916-17-1
Neohesperidin 13241-33-3
Neohesperidin dihydrochalcone (Nhdc) 20702-77-6
Nobiletin (Hexamethoxyflavone) 478-01-3
Oleanolic Acid (Caryophyllin) 508-02-1
Oridonin (Isodonol) 28957-04-2
Orotic acid (6-Carboxyuracil) 65-86-1
Osthole (Osthol) 484-12-8
Oxymatrine (Matrine N-oxide) 16837-52-8
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Quercetin dihydrate (Sophoretin) 6151-25-3
Resveratrol 501-36-0









Shikimic acid (Shikimate) 138-59-0
Shikonin 54952-43-1
Silibinin (Silybin) 22888-70-6
Silymarin (Silybin B) 65666-07-1
Sinomenine (Cucoline) 115-53-7
Sodium Danshensu 67920-52-9, 23028-17-3





Tanshinone IIA (Tanshinone B) 568-72-9
Taxifolin (Dihydroquercetin) 480-18-2
Tetrahydropapaverine hydrochloride 6429-04-5
Tetrandrine (Fanchinine) 518-34-3, 32434-13-2 (2HCL)
Triptolide 38748-32-2
Troxerutin 7085-55-4




Yohimbine hydrochloride (Antagonil) 65-19-0
β-Sitosterol 83-46-5
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Table A2: Bliss indices demonstrate strong synergism between parthenolide and 
shikonin in BCP-ALL 
Selectively toxic compounds were evaluated between 250 nM - 15 µM. Broadly toxic 
compounds were evaluated between 10 nM - 5 µM. Bliss indices were calculated from cell 
viability data following 24-hour combination treatment. Values >0.1 are shown in bold. 
BCP-ALL, precursor B-cell acute lymphoblastic leukemia. 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM -0.0069 0.0102 0.0340 0.0210 0.0067 -0.0002 -0.0901
500 nM -0.0065 -0.0020 0.0233 -0.0139 -0.0074 -0.0164 -0.0073
750 nM -0.0065 -0.0016 0.0217 0.0113 0.0040 -0.0191 -0.0049
1 µm -0.0068 -0.0025 0.0389 0.0229 0.0139 0.0091 -0.0040
5 µM -0.0062 0.0007 0.0057 -0.0143 -0.0200 -0.0345 -0.0026
10 µm -0.0067 -0.0064 0.0198 0.0288 0.0039 0.0096 -0.0005
15 µm -0.0074 0.0236 0.0396 0.0234 0.0659 0.1931 0.0009
250 nM -0.0201 -0.0198 0.0444 -0.0054 -0.0210 -0.0086 0.0084
500 nM -0.0173 -0.0074 0.0157 -0.0223 -0.0319 0.0041 0.0071
750 nM -0.0141 -0.0518 -0.0340 -0.0433 -0.0678 -0.0431 0.0045
1 µm -0.0143 0.0166 0.0264 0.0154 -0.0337 0.0113 0.0055
5 µM -0.0088 0.0180 0.0301 0.0081 -0.0116 -0.0150 0.0026
10 µm -0.0065 0.0146 0.0221 -0.0140 -0.0252 -0.0465 0.0008
15 µm -0.0058 0.0081 0.0244 -0.0182 -0.0246 -0.0294 -0.0010
10 nM -0.0269 0.0243 0.0660 0.0310 0.0245 0.0622 0.0034
50 nM -0.0267 -0.0145 0.0418 0.0426 0.0020 0.0657 0.0029
100 nM -0.0271 -0.0101 0.0782 0.0758 0.0718 -0.0878 0.0006
250 nM -0.0261 0.0328 0.0751 0.1936 0.0666 0.1072 0.0087
500 nM -0.0221 0.1748 0.1413 0.1684 0.0901 0.0386 0.0083
1 µM -0.0028 -0.2233 -0.0231 -0.2358 -0.1843 0.0012 -0.0026
5 µM -0.0058 0.0672 0.2152 0.0062 0.1139 0.0414 0.0005
10 nM -0.0255 -0.0047 0.0403 0.0017 0.0064 0.0007 0.0001
50 nM -0.0241 -0.0023 0.1467 0.1877 0.2923 0.4710 0.0042
100 nM -0.0234 0.0125 0.2371 0.4440 0.5623 0.5251 0.0050
250 nM -0.0100 0.0819 0.1312 0.2929 0.2778 0.2937 -0.0063
500 nM -0.0065 0.0826 0.1184 0.1898 0.1861 0.1977 -0.0095
1 µM -0.0053 0.0158 0.1110 0.1523 0.1613 0.1580 -0.0103
5 µM -0.0058 0.1134 0.1200 0.1598 0.1747 0.1750 -0.0093
10 nM -0.0254 -0.0116 0.0193 -0.0095 -0.0657 -0.0192 -0.0001
50 nM -0.0262 -0.0087 0.0246 -0.0014 -0.0085 -0.0207 -0.1106
100 nM -0.0263 -0.0150 0.0318 0.0229 0.0272 -0.0208 -0.0035
250 nM -0.0262 -0.0366 0.0225 -0.0814 -0.1112 -0.0148 -0.0007
500 nM -0.0273 -0.0149 0.0275 -0.0336 -0.0733 -0.0632 -0.0485
1 µM -0.0266 -0.0346 0.0458 -0.0506 -0.0614 0.0182 -0.0016
5 µM -0.0259 -0.0315 -0.0056 -0.0144 -0.0405 -0.0064 -0.0022
250 nM -0.0007 0.0038 0.0110 0.0146 0.0154 0.0167 -0.0107
500 nM -0.0007 0.0055 0.0142 0.0219 0.0215 0.0201 -0.0116
750 nM -0.0005 0.0007 0.0117 0.0135 0.0130 0.0128 -0.0124
1 µm -0.0005 0.0003 0.0131 0.0134 0.0120 0.0139 -0.0122
5 µM -0.0005 0.0030 0.0115 0.0147 0.0134 0.0123 -0.0104
10 µm -0.0005 0.0019 0.0104 0.0128 0.0136 0.0105 -0.0094

















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM -0.0057 -0.0099 -0.0230 -0.0228 -0.0256 -0.0322 -0.0044
500 nM -0.0060 -0.0056 -0.0089 -0.0172 -0.0288 -0.0365 -0.0065
750 nM -0.0063 0.0019 -0.0056 -0.0087 -0.0226 -0.0195 -0.0062
1 µm -0.0061 -0.0133 -0.0141 -0.0145 -0.0308 -0.0159 -0.0038
5 µM -0.0064 0.0316 -0.0080 -0.0127 0.0018 -0.0146 -0.0024
10 µm -0.0063 -0.0142 -0.0154 -0.0034 -0.0141 -0.0192 -0.0029
15 µm -0.0064 -0.0096 -0.0102 -0.0010 0.0119 0.0091 -0.0032
250 nM -0.0266 -0.0248 -0.0220 -0.0244 -0.0390 -0.0368 0.0030
500 nM -0.0267 -0.0177 -0.0203 -0.0343 -0.0010 0.0123 0.0043
750 nM -0.0248 -0.0304 -0.0375 0.0035 -0.0195 0.0344 0.0028
1 µm -0.0236 -0.0437 -0.0158 -0.0020 -0.0326 0.0840 0.0029
5 µM -0.0136 -0.0012 0.0111 -0.0132 -0.0336 -0.0125 0.0007
10 µm -0.0105 -0.0205 -0.0343 -0.0212 -0.0322 -0.0385 0.0003
15 µm -0.0101 -0.0103 0.0054 -0.0160 -0.0122 0.0080 -0.0005
10 nM -0.0291 -0.0382 -0.0166 -0.0086 -0.0097 0.0213 0.0002
50 nM -0.0289 -0.0806 -0.0227 -0.0194 -0.0541 0.0116 -0.0005
100 nM -0.0292 -0.0460 -0.0186 -0.0146 0.0474 -0.1068 -0.0038
250 nM -0.0289 0.0186 -0.0438 0.0855 0.0029 0.1024 -0.0009
500 nM -0.0289 0.2008 0.2951 0.4401 0.1345 0.4816 0.0044
1 µM -0.0200 0.1614 0.2103 0.2371 0.4403 0.3081 0.0023
5 µM -0.0008 -0.2454 -0.3716 -0.1089 -0.5082 -0.1447 -0.0049
10 nM -0.0286 -0.0534 -0.0429 -0.0368 -0.0362 -0.0267 -0.0033
50 nM -0.0290 -0.0034 0.0666 0.0624 0.0856 0.2586 -0.0025
100 nM -0.0285 -0.0141 0.1054 0.1654 0.2590 0.2178 -0.0025
250 nM -0.0208 0.0097 0.0586 0.2179 0.2364 0.3191 -0.0012
500 nM -0.0173 0.0167 0.0946 0.2490 0.2078 0.2917 -0.0018
1 µM -0.0168 0.0229 0.0820 0.2069 0.2409 0.2816 -0.0018
5 µM -0.0144 -0.0232 0.0336 0.0991 0.2197 0.2453 -0.0016
10 nM -0.0290 -0.0187 -0.0288 -0.0352 -0.0216 -0.0122 -0.0001
50 nM -0.0289 -0.0655 -0.0398 -0.0394 -0.0478 -0.0480 -0.0050
100 nM -0.0291 -0.0363 -0.0432 -0.0189 0.0546 -0.0272 -0.0045
250 nM -0.0293 -0.0295 -0.0047 -0.0483 -0.0529 0.0158 -0.0033
500 nM -0.0288 -0.0515 -0.0243 -0.0571 -0.0742 -0.0793 -0.0018
1 µM -0.0294 -0.0508 -0.0146 -0.0224 0.0298 0.0450 -0.0010
5 µM -0.0286 -0.0379 -0.0179 0.0025 0.0717 0.0512 -0.0031
250 nM -0.0001 0.0007 0.0013 0.0018 0.0021 0.0016 -0.0061
500 nM -0.0001 0.0004 0.0007 0.0010 0.0007 0.0006 -0.0067
750 nM 0.0000 0.0002 0.0002 0.0007 0.0004 0.0003 -0.0071
1 µm -0.0001 -0.0003 0.0006 0.0005 0.0004 0.0004 -0.0057
5 µM 0.0000 0.0002 0.0001 0.0005 0.0004 0.0000 -0.0048
10 µm -0.0001 0.0000 0.0002 0.0004 0.0001 0.0002 -0.0049

















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM 0.0020 0.0119 0.0019 0.0023 0.0125 0.0209 -0.0023
500 nM 0.0023 0.0048 0.0128 0.0122 0.0194 0.0325 0.0015
750 nM 0.0024 0.0087 0.0168 0.0086 0.0256 0.0302 0.0020
1 µm 0.0022 -0.0157 0.0002 0.0033 0.0132 0.0256 0.0028
5 µM 0.0026 -0.0091 0.0153 0.0053 0.0277 0.0313 0.0061
10 µm 0.0025 0.0143 0.0059 0.0191 0.0380 0.0436 0.0052
15 µm 0.0025 0.0082 0.0120 0.0086 0.0115 -0.0093 0.0034
250 nM 0.0111 0.0674 0.0499 0.0175 0.0108 0.0500 0.0176
500 nM 0.0064 -0.0028 -0.0275 -0.0744 -0.0902 -0.0325 -0.0180
750 nM 0.0047 0.0096 0.0029 -0.0043 -0.0394 -0.0185 -0.0124
1 µm 0.0040 -0.0196 -0.0081 -0.0337 -0.0288 -0.0405 -0.0048
5 µM 0.0035 -0.0075 -0.0065 -0.0143 -0.0002 0.0123 0.0029
10 µm 0.0037 0.0155 0.0013 -0.0005 0.0181 0.0321 0.0100
15 µm 0.0035 0.0057 0.0100 0.0013 0.0120 0.0358 0.0082
10 nM 0.0187 0.0388 0.0484 0.0584 0.0991 0.1278 0.0541
50 nM 0.0182 0.0809 0.0075 -0.0173 0.0513 0.0626 0.0625
100 nM 0.0175 -0.0409 0.0054 0.0103 0.0046 0.0339 -0.0040
250 nM 0.0119 0.0119 -0.0987 -0.2503 -0.2728 -0.2432 0.0065
500 nM 0.0068 0.3209 0.0844 0.0192 0.1534 -0.0129 0.0027
1 µM 0.0024 -0.0961 -0.1519 -0.2143 -0.3960 -0.1586 0.0048
5 µM 0.0053 -0.0909 -0.2003 -0.6052 -0.0354 -0.1587 0.0115
10 nM 0.0171 0.0086 0.0305 -0.0130 0.0690 0.0827 0.0491
50 nM 0.0168 0.0082 0.0241 0.0064 0.0493 0.0983 0.0528
100 nM 0.0160 -0.0201 -0.0063 -0.0548 0.0342 0.0962 0.0729
250 nM 0.0153 -0.0043 0.0499 0.0604 0.1557 0.2301 0.0751
500 nM 0.0134 0.0485 0.0566 0.1243 0.1813 0.2939 0.0670
1 µM 0.0126 0.0348 0.0623 0.0809 0.2257 0.3156 0.0615
5 µM 0.0112 -0.0139 0.0298 0.0114 0.1192 0.2156 0.0451
10 nM 0.0160 -0.0244 -0.0049 -0.0313 0.0034 0.0016 0.0386
50 nM 0.0166 0.0080 0.0169 -0.0173 0.0075 0.0573 0.0336
100 nM 0.0164 0.0081 0.0225 -0.0421 0.0172 0.0434 -0.0035
250 nM 0.0165 0.0132 0.0122 -0.0115 0.0178 0.0505 0.0458
500 nM 0.0163 0.0201 0.0007 -0.0350 0.0176 0.0256 0.0460
1 µM 0.0164 0.0119 -0.0149 -0.0326 0.0458 0.0420 0.0382
5 µM 0.0162 0.0163 0.0334 -0.0146 0.0281 0.0660 0.0749
250 nM 0.0050 0.0016 0.0139 0.0081 0.0286 0.0370 -0.0110
500 nM 0.0044 -0.0064 -0.0065 -0.0049 0.0109 0.0168 -0.0151
750 nM 0.0043 0.0091 0.0198 0.0087 0.0227 0.0310 -0.0108
1 µm 0.0042 0.0056 0.0177 0.0081 0.0213 0.0330 -0.0224
5 µM 0.0039 0.0097 0.0133 -0.0003 0.0225 0.0238 -0.0179
10 µm 0.0039 0.0114 0.0102 0.0043 0.0148 0.0243 0.0029

















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM -0.0047 -0.0055 0.0036 0.0002 -0.0010 -0.0064 -0.0761
500 nM -0.0047 -0.0029 -0.0022 0.0006 -0.0055 -0.0014 -0.0708
750 nM -0.0053 0.0074 0.0130 0.0090 0.0137 0.0104 -0.0611
1 µm -0.0049 -0.0068 -0.0032 0.0069 0.0030 0.0037 -0.0638
5 µM -0.0053 -0.0066 0.0062 0.0005 0.0049 0.0035 -0.0645
10 µm -0.0054 0.0047 0.0162 0.0111 0.0081 0.0096 -0.0559
15 µm -0.0053 -0.0002 -0.0076 -0.0323 -0.0073 -0.0289 -0.0707
250 nM -0.0430 -0.0404 0.0056 -0.0389 -0.0578 -0.0114 0.0170
500 nM -0.0393 -0.0331 0.0051 -0.0577 -0.0515 -0.0275 0.0197
750 nM -0.0314 -0.0146 0.0207 -0.0116 -0.0289 -0.0319 0.0535
1 µm -0.0266 -0.0688 -0.0431 -0.0569 -0.1144 -0.0818 0.0645
5 µM -0.0164 -0.0033 0.0068 -0.0013 -0.0080 0.0082 0.0079
10 µm -0.0154 -0.0201 0.0138 -0.0065 -0.0160 0.0016 0.0160
15 µm -0.0159 -0.0046 0.0109 -0.0064 -0.0134 0.0037 0.0159
10 nM -0.0493 -0.0534 -0.0107 -0.0195 -0.0202 -0.0027 0.2587
50 nM -0.0515 -0.0207 0.0379 0.0244 0.0091 0.0459 0.2171
100 nM -0.0509 -0.0526 0.0213 -0.0318 -0.0029 0.0297 0.0946
250 nM -0.0509 -0.0144 0.0629 -0.0076 0.0095 0.0461 0.2251
500 nM -0.0499 -0.0787 0.1357 0.0256 0.2402 0.2281 0.3362
1 µM -0.0481 -0.0885 0.1766 0.1580 0.0716 0.2155 0.2062
5 µM -0.0510 -0.0362 0.1414 0.3836 0.0130 0.0336 0.1865
10 nM -0.0498 -0.0306 0.0107 -0.0377 -0.0345 0.0410 0.1898
50 nM -0.0503 -0.0319 0.0217 -0.0241 0.0056 0.0650 0.2500
100 nM -0.0501 -0.0345 0.0358 -0.0075 0.0434 0.1139 0.3815
250 nM -0.0459 -0.0683 0.0573 -0.0166 0.0943 0.1744 0.3111
500 nM -0.0435 -0.0141 0.0927 0.0604 0.1420 0.1588 0.3636
1 µM -0.0438 0.0074 0.0919 0.0876 0.1579 0.2143 0.3588
5 µM -0.0416 -0.0166 0.0782 0.0137 0.1062 0.1912 0.3662
10 nM -0.0492 -0.0341 0.0607 -0.0221 0.0062 0.0306 0.0241
50 nM -0.0504 -0.0214 0.0262 -0.0075 -0.0121 0.0283 0.2384
100 nM -0.0494 -0.0231 0.0067 -0.0324 -0.0115 0.0142 -0.0441
250 nM -0.0489 -0.0549 0.0066 -0.0349 -0.0227 -0.0124 0.0466
500 nM -0.0486 -0.0515 0.0056 -0.0525 -0.0431 -0.0185 0.1758
1 µM -0.0484 -0.0519 0.0063 -0.0507 -0.0192 -0.0375 -0.0323
5 µM -0.0477 -0.0517 -0.0097 -0.0407 -0.0484 -0.0495 0.0517
250 nM -0.0066 0.0042 0.0272 0.0306 0.0369 0.0563 0.0637
500 nM -0.0066 0.0003 0.0201 0.0215 0.0251 0.0509 0.0618
750 nM -0.0067 -0.0036 0.0199 0.0189 0.0367 0.0533 0.0721
1 µm -0.0066 -0.0014 0.0164 0.0277 0.0349 0.0495 0.0668
5 µM -0.0065 0.0017 0.0195 0.0271 0.0433 0.0535 0.0675
10 µm -0.0065 -0.0005 0.0173 0.0248 0.0335 0.0560 0.0696



















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM 0.0033 0.0065 -0.0009 -0.0038 -0.0022 -0.0095 -0.0556
500 nM 0.0034 -0.0048 0.0064 -0.0093 -0.0025 -0.0051 -0.0714
750 nM 0.0036 -0.0062 0.0075 -0.0128 -0.0004 -0.0017 -0.0560
1 µm 0.0035 -0.0048 0.0007 -0.0149 -0.0037 -0.0052 -0.0554
5 µM 0.0035 0.0354 0.0059 -0.0049 0.0039 0.0064 -0.0450
10 µm 0.0036 -0.0124 0.0014 0.0063 0.0137 0.0079 -0.0491
15 µm 0.0036 -0.0072 -0.0042 -0.0040 0.0848 0.0761 -0.0447
250 nM 0.0193 -0.0210 0.0580 0.0117 0.0316 0.0263 0.0218
500 nM 0.0177 -0.0088 0.0577 0.0056 0.0213 0.0220 0.0069
750 nM 0.0150 0.0295 0.0710 0.0480 0.0478 0.0437 0.0446
1 µm 0.0121 -0.0547 -0.0319 0.0104 -0.0296 -0.0594 0.0147
5 µM 0.0019 -0.0124 0.0087 -0.0011 -0.0176 -0.0145 -0.0437
10 µm 0.0010 -0.0028 0.0038 -0.0025 -0.0069 -0.0039 -0.0312
15 µm 0.0009 -0.0039 -0.0004 -0.0048 -0.0064 -0.0079 -0.0303
10 nM 0.0201 -0.0413 0.0530 0.0082 0.0652 0.0464 0.0711
50 nM 0.0199 -0.0369 0.0291 -0.0158 0.0373 0.0419 0.0538
100 nM 0.0203 -0.0214 0.0564 0.0038 0.0182 0.0763 -0.0315
250 nM 0.0199 -0.0597 0.1053 0.0171 0.2110 0.0749 0.0530
500 nM 0.0183 -0.0747 0.3808 0.2719 -0.0071 0.0506 0.0968
1 µM 0.0200 0.0165 0.1470 0.1443 0.3004 0.0340 -0.0338
5 µM 0.0203 0.0789 0.2944 0.0612 0.3246 0.0089 -0.0431
10 nM 0.0198 -0.0218 0.0244 -0.0184 0.0418 0.0823 0.1014
50 nM 0.0197 -0.0181 0.0295 0.0290 0.0404 0.0393 0.0932
100 nM 0.0199 -0.0068 0.0694 -0.0336 0.0577 0.0897 0.1248
250 nM 0.0189 -0.0282 0.0869 -0.0092 0.1214 0.1756 0.1310
500 nM 0.0176 -0.0142 0.0663 -0.0071 0.1034 0.1271 0.1401
1 µM 0.0177 -0.0483 0.1054 0.0596 0.1375 0.1900 0.1097
5 µM 0.0174 -0.0424 0.0887 0.0128 0.0960 0.1007 0.1425
10 nM 0.0198 0.0043 0.0537 0.0231 0.0775 0.0644 0.0095
50 nM 0.0196 -0.0350 0.0525 0.0077 0.0427 0.0520 0.1465
100 nM 0.0197 0.0015 0.0367 -0.0047 0.0538 0.0531 -0.0690
250 nM 0.0197 -0.0215 0.0622 0.0074 0.0926 0.0399 -0.0164
500 nM 0.0197 -0.0219 0.0273 -0.0006 0.0545 0.0262 0.1119
1 µM 0.0200 -0.0401 0.0514 -0.0097 0.0470 0.0196 -0.0669
5 µM 0.0200 -0.0327 0.0410 -0.0068 0.0186 -0.0008 -0.0073
250 nM 0.0012 0.0027 0.0128 0.0069 0.0111 0.0135 -0.0162
500 nM 0.0009 -0.0005 0.0045 0.0011 0.0050 0.0070 -0.0220
750 nM 0.0010 -0.0008 0.0050 0.0017 0.0068 0.0068 -0.0221
1 µm 0.0010 -0.0015 0.0072 0.0056 0.0072 0.0086 -0.0231
5 µM 0.0008 0.0004 0.0043 0.0008 0.0032 0.0045 -0.0244
10 µm 0.0009 0.0014 0.0083 0.0044 0.0056 0.0078 -0.0217















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM -0.0083 0.0243 0.0964 -0.0491 -0.0273 0.0224 -0.0915
500 nM -0.0083 -0.0783 0.0275 -0.0677 -0.0880 -0.0623 -0.1701
750 nM -0.0083 -0.0455 0.0114 -0.1042 -0.0874 -0.0542 -0.1979
1 µm -0.0083 -0.0383 0.0141 -0.1231 -0.0786 -0.0696 -0.1434
5 µM -0.0079 -0.0143 0.1574 0.0369 0.0684 0.1386 0.0415
10 µm -0.0049 -0.0481 0.0055 -0.0631 -0.0615 -0.0413 -0.0900
15 µm -0.0050 -0.0217 0.0034 -0.0375 -0.0119 -0.0266 -0.0394
250 nM -0.0104 -0.0463 0.1014 -0.0213 -0.0312 -0.0002 -0.0081
500 nM -0.0107 -0.0205 0.0754 -0.0533 -0.0694 0.0152 -0.0175
750 nM -0.0109 0.0112 0.1006 -0.0820 0.0185 0.0972 0.0095
1 µm -0.0106 -0.0045 0.0909 -0.1091 -0.0821 -0.0154 -0.0246
5 µM -0.0105 0.0253 0.0918 -0.0734 -0.0561 -0.0140 -0.0776
10 µm -0.0098 -0.0440 0.0219 -0.0640 -0.1536 -0.0555 -0.1222
15 µm -0.0098 -0.0360 0.0708 -0.1240 -0.0763 -0.0468 -0.1249
10 nM -0.0111 -0.0208 0.0376 -0.1030 -0.1021 -0.0613 -0.1017
50 nM -0.0111 0.0041 0.0151 -0.0814 -0.0957 -0.0781 -0.0704
100 nM -0.0112 -0.0567 0.0467 -0.1189 -0.1075 -0.0370 -0.1147
250 nM -0.0113 -0.0616 0.0706 -0.0932 -0.0288 -0.0109 -0.0548
500 nM -0.0115 0.0072 0.0885 -0.0301 0.0557 0.0278 -0.0064
1 µM -0.0118 0.0462 0.1308 0.0382 0.0208 0.0487 0.0613
5 µM -0.0110 -0.0109 0.0731 -0.0182 0.0723 0.0162 0.0092
10 nM -0.0118 0.0218 0.1146 -0.0848 0.0011 -0.0019 0.0149
50 nM -0.0115 -0.0599 0.0621 -0.0782 -0.0046 0.0443 -0.0134
100 nM -0.0117 -0.0228 0.0386 -0.1529 -0.0300 0.0312 -0.0101
250 nM -0.0114 -0.0354 -0.0351 -0.0974 -0.0020 0.0193 -0.0174
500 nM -0.0114 0.0304 0.0794 -0.0950 -0.0452 0.0332 0.0383
1 µM -0.0115 0.0254 0.1024 -0.0755 0.0289 0.0743 0.0196
5 µM -0.0114 -0.0333 0.1023 -0.0714 0.0127 0.0585 -0.0047
10 nM -0.0112 -0.0646 0.0451 -0.0969 -0.0439 0.0433 0.0293
50 nM -0.0114 -0.0340 0.0260 -0.1290 -0.0495 0.0434 -0.0161
100 nM -0.0112 -0.0686 0.0881 -0.0906 -0.0111 0.0279 0.0591
250 nM -0.0114 0.0134 0.1134 -0.0478 0.0102 0.0639 0.0007
500 nM -0.0112 -0.0347 0.0852 -0.1333 -0.0475 -0.0005 -0.0359
1 µM -0.0112 0.0249 0.0856 -0.0685 -0.0493 -0.0108 -0.0105
5 µM -0.0111 0.0075 0.1285 -0.0974 -0.0644 -0.0139 -0.0101
250 nM -0.0044 -0.0287 -0.0128 -0.0798 -0.0296 -0.0181 -0.0177
500 nM -0.0043 -0.0382 0.0079 -0.0462 -0.0256 -0.0027 -0.0419
750 nM -0.0046 0.0005 0.0204 -0.0513 -0.0054 0.0125 -0.0282
1 µm -0.0046 -0.0128 0.0297 -0.0343 0.0119 0.0203 -0.0050
5 µM -0.0045 -0.0006 0.0296 -0.0339 0.0021 0.0247 0.0069
10 µm -0.0044 -0.0167 0.0224 -0.0348 -0.0137 0.0127 -0.0038
















































Table A2, continued 
 
  
0 nM 50 nM 250 nM 500 nM 750 nM 1 µM 5 µM
250 nM -0.0457 0.0025 0.0330 -0.0066 0.0139 -0.0167 -0.1013
500 nM -0.0439 -0.0741 -0.0014 -0.0298 -0.0082 -0.0564 -0.1584
750 nM -0.0448 -0.0200 0.0242 -0.0156 -0.0054 -0.0573 -0.1602
1 µm -0.0436 -0.0303 -0.0150 -0.0411 -0.0611 -0.0825 -0.1530
5 µM -0.0393 -0.0246 0.0123 -0.0428 0.0131 -0.0150 -0.1679
10 µm -0.0345 -0.0460 -0.0214 -0.0098 -0.0263 -0.0350 -0.1276
15 µm -0.0340 0.0060 0.0133 -0.0079 -0.0104 -0.0291 -0.1012
250 nM -0.0667 -0.0329 -0.0131 -0.0356 -0.0218 -0.0920 -0.0070
500 nM -0.0677 -0.0985 -0.0460 -0.0865 -0.0802 -0.0838 -0.0556
750 nM -0.0693 -0.0568 -0.0394 -0.0653 0.0299 -0.0766 0.0414
1 µm -0.0700 -0.0244 -0.0167 -0.1084 -0.0571 -0.0336 0.0460
5 µM -0.0618 -0.0148 -0.0355 -0.0685 -0.0412 -0.0475 -0.0345
10 µm -0.0590 -0.0804 -0.0663 -0.0835 -0.0882 -0.0789 -0.0736
15 µm -0.0627 -0.0187 0.0726 -0.0167 0.0802 0.0312 0.0719
10 nM -0.0685 -0.0204 -0.0093 -0.0325 -0.0161 -0.0226 -0.0565
50 nM -0.0695 -0.0017 0.0239 0.0022 0.0739 -0.0746 0.0020
100 nM -0.0705 -0.0487 0.0693 -0.0050 0.0084 -0.0155 -0.0699
250 nM -0.0698 -0.0563 -0.0338 0.0189 0.0479 -0.0589 -0.0805
500 nM -0.0728 -0.0758 0.0217 0.0568 0.0990 0.0163 0.0831
1 µM -0.0662 -0.1043 0.1083 -0.0346 -0.0214 -0.0832 -0.0244
5 µM -0.0654 -0.0535 0.0552 0.0449 0.1243 0.0009 0.1027
10 nM -0.0732 0.0262 -0.0362 -0.0554 -0.0794 -0.0623 0.0220
50 nM -0.0731 0.0270 0.0671 -0.0076 0.0598 -0.0102 0.0346
100 nM -0.0729 0.0071 0.0947 0.0202 0.0336 0.0252 0.0701
250 nM -0.0724 -0.0424 0.0200 0.0153 -0.0040 0.0272 0.0680
500 nM -0.0726 -0.0649 0.0158 -0.0011 -0.0154 -0.0274 0.0266
1 µM -0.0725 0.0008 0.0555 -0.0428 0.0203 0.0495 0.0846
5 µM -0.0707 0.0347 0.0488 0.0166 0.0625 0.0503 0.0589
10 nM -0.0708 -0.0395 0.0518 -0.0409 0.0599 0.0275 0.0347
50 nM -0.0736 -0.0296 0.0235 -0.0622 0.0121 -0.0612 0.0329
100 nM -0.0689 -0.0427 0.0249 -0.0272 0.0045 -0.0834 0.0046
250 nM -0.0709 -0.0018 -0.0418 -0.0169 0.0186 0.0062 0.0420
500 nM -0.0744 0.0500 0.0434 0.0171 -0.0013 0.0271 0.0582
1 µM -0.0722 -0.0296 0.0323 -0.0170 0.0572 -0.0694 -0.0279
5 µM -0.0664 -0.0538 -0.0497 -0.0406 -0.0400 -0.0811 -0.0256
250 nM -0.0395 0.0158 -0.0095 -0.0172 0.0150 0.0078 -0.0866
500 nM -0.0393 -0.0173 -0.0154 -0.0694 -0.0309 -0.0035 -0.1031
750 nM -0.0415 -0.0100 -0.0129 0.0045 0.0157 -0.0119 -0.0519
1 µm -0.0432 0.0049 0.0536 -0.0006 0.0457 0.0148 -0.0383
5 µM -0.0414 -0.0055 -0.0171 -0.0254 0.0233 -0.0524 -0.0999
10 µm -0.0389 -0.0224 -0.0006 -0.0484 -0.0136 -0.0004 -0.0589

















































Table A3: Comprehensive list of compounds included in the Cambridge cancer 
compound library 
Screening library was purchased from Selleck Chemicals, formatted in to 384-well plates, 















































BIRB 796 (Doramapimod) 285983-48-4
Bitopertin 845614-11-1
BIX 01294 1392399-03-9
































Dacomitinib (PF299804, PF299) 1110813-31-4



































Fingolimod (FTY720) HCl 162359-56-0
Flavopiridol HCl 131740-09-5
Fludarabine 21679-14-1

























INK 128 (MLN0128) 1224844-38-5



















































NVP-BSK805 2HCl 1092499-93-8 (free base)
Obatoclax Mesylate (GX15-070) 803712-79-0



















































































Temsirolimus (CCI-779, NSC 683864) 162635-04-3
TG101348 (SAR302503) 936091-26-8
Evofosfamide (TH-302) 918633-87-1









Trichostatin A (TSA) 58880-19-6
Triptolide (PG490) 38748-32-2
TW-37 877877-35-5
Valproic acid sodium salt (Sodium valproate) 1069-66-5
Vandetanib (ZD6474) 443913-73-3
Vatalanib (PTK787) 2HCl 212141-51-0
Veliparib (ABT-888) 912444-00-9
Vemurafenib (PLX4032, RG7204) 918504-65-1
Venetoclax (ABT-199, GDC-0199) 1257044-40-8
Vincristine 2068-78-2
Vismodegib (GDC-0449) 879085-55-9
Volasertib (BI 6727) 755038-65-4
Vorinostat (SAHA, MK0683) 149647-78-9













Appendix B: Supplementary Figures 
 
 
Figure B1: Minimal differences in viability were observed between PTL and DMAPT 
in leukemia and normal cells 
Viability was assessed by ATP luminescence following 24-hour treatment with PTL or 
DMAPT at 1 or 5 µM final concentration. Viability is expressed relative to vehicle control 
for each cell line. Standard deviation calculated from 6 replicates. High reproducibility led 
to statistical significance between PTL and DMAPT at both concentrations. However, the 
difference was small (<10% in most cases) and was considered acceptable given the 
improvements in solubility and expected bioavailability in vivo. PTL, parthenolide; 
DMAPT, dimethylaminoparthenolide.  
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Figure B2: DMAPT and SHK are synergistic at a 1:1 ratio in RCH-ACV and Reh 
cells according to Chou-Talalay combination index analysis 
Combination index plots for RCH-ACV (A) and Reh (C) demonstrate the synergistic 
window for DMAPT:SHK. CI >1 indicates antagonism, CI equal to one indicates an 
additive effect, and CI <1 indicates synergism. Synergism was found between Fa 0.1 – 0.6 
and >0.1 for RCH-ACV and Reh cells, respectively. Isobologram for RCH-ACV (B) 
indicates synergism at Fa = 0.5 and below. Isobologram for Reh (D) indicates synergism 
at Fa = 0.9 and below. CI, combination index; Fa, fraction affected; DMAPT, 
dimethylaminoparthenolide; SHK, shikonin; Dose A (nM), DMAPT; Dose B (nM), SHK. 
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Appendix C: Induction Therapy Roadmap Forms 
Form C1: AALL0932 Induction Therapy Roadmap 
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Form C3: AALL1122 Induction Therapy Roadmap  
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Form C3: AALL1122 Induction Therapy Roadmap, continued  
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Form C3: AALL1122 Induction Therapy Roadmap, continued  
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